

Approved



**Botswana**  
**Country Operational Plan**  
**FY 2018**



## Budget Summary Reports

### Summary of Planned Funding by Agency and Funding Source

Agency	Funding Source			Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline Amount
	GAP	GHP-State	GHP-USAID			
State		57,662		57,662	183,601	241,263
USAID		28,472,965	0	28,472,965	344,978	28,817,943
DOD		1,745,014		1,745,014	0	1,745,014
PC		3,458,127		3,458,127	0	3,458,127
HHS/CDC	2,196,250	24,641,868		26,838,118	1,934,521	28,772,639
HHS/HRSA		6,219,204		6,219,204	0	6,219,204
State/AF		168,661		168,661	816,399	985,060
<b>Total</b>	<b>2,196,250</b>	<b>64,763,501</b>	<b>0</b>	<b>66,959,751</b>	<b>3,279,499</b>	<b>70,239,250</b>

### Summary of Planned Funding by Budget Code and Agency

Budget Code	Agency							Total
	State	DOD	HHS/CDC	HHS/HRSA	PC	State/AF	USAID	
CIRC		1,008,167	3,371,385	0	0		0	4,379,552
HBHC	18,740	0	1,622,974	613,442	423,603		8,525,858	11,204,617
HKID	5,766	0	0	0	233,160	37,500	3,203,785	3,480,211
HLAB		167,000	26,518	0	0		0	193,518
HMBL		0	0	0	0		0	0
HMIN		0	0	0	0		0	0
HTXD		0	0	0	0		320,092	320,092
HTXS		80,000	11,010,437	826,311	533,426		2,931,550	15,381,724
HVAB		0	0	0	0		1,429,625	1,429,625
HVCT		188,514	1,281,012	4,479,451	0		3,928,133	9,877,110
HVMS	33,156	74,444	4,510,149		1,631,394		1,770,017	8,019,160

Approved



HVOP		26,889	800,000	0	212,941	131,161	2,869,389	<b>4,040,380</b>
HVSI		200,000	108,163	0	0		163,732	<b>471,895</b>
HVTB		0	2,486,916	0	0		1,718,476	<b>4,205,392</b>
IDUP		0	0	0	0		0	<b>0</b>
MTCT		0	596,053	0	0		226,135	<b>822,188</b>
OHSS		0	0	0	0	0	290,406	<b>290,406</b>
PDCS		0	139,200	0	423,603		1,095,767	<b>1,658,570</b>
PDTX		0	885,311	300,000	0		0	<b>1,185,311</b>
	<b>57,662</b>	<b>1,745,014</b>	<b>26,838,118</b>	<b>6,219,204</b>	<b>3,458,127</b>	<b>168,661</b>	<b>28,472,965</b>	<b>66,959,751</b>



## Technical Areas

### Technical Area Summary

#### Technical Area: Care

Budget Code	Budget Code Planned Amount
HBHC	8,986,351
HKID	3,248,940
HVTB	3,790,773
PDCS	1,138,763
<b>Total Technical Area Planned Funding:</b>	<b>17,164,827</b>

#### Technical Area: Governance and Systems

Budget Code	Budget Code Planned Amount
HLAB	167,000
HVSI	200,000
OHSS	260,000
<b>Total Technical Area Planned Funding:</b>	<b>627,000</b>

#### Technical Area: Prevention

Budget Code	Budget Code Planned Amount
CIRC	4,184,500
HMBL	0
HMIN	0
HVAB	1,429,625
HVCT	9,430,747
HVOP	3,974,283
IDUP	0
MTCT	771,432
<b>Total Technical Area Planned Funding:</b>	<b>19,790,587</b>

Approved



**Technical Area: Treatment**

<b>Budget Code</b>	<b>Budget Code Planned Amount</b>
HTXD	100,118
HTXS	13,101,004
PDTX	1,087,500
<b>Total Technical Area Planned Funding:</b>	<b>14,288,622</b>



### Technical Area Summary Indicators and Targets

Indicator Number	Label	2019
PMTCT_STAT_DSD	PMTCT_STAT_DSD Number and percentage of pregnant women with known status (includes women who were tested for HIV and received their results) (DSD)	100 %
	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	12
	Number of new ANC and L&D clients	12
	PMTCT_STAT_D_DSD_Age_Sex 25-29, Female	3
	PMTCT_STAT_D_DSD_Age_Sex 30-34, Female	6
	PMTCT_STAT_D_DSD_Age_Sex 35-39, Female	2
	PMTCT_STAT_D_DSD_Age_Sex 40-49, Female	1
	PMTCT_STAT_N_DSD_Age_Sex_ KnownNewResult 25-29, Female, Known at Entry Positive	3
	PMTCT_STAT_N_DSD_Age_Sex_ KnownNewResult 30-34, Female, Known at Entry Positive	6
	PMTCT_STAT_N_DSD_Age_Sex_ KnownNewResult 35-39, Female, Known at Entry Positive	2
	PMTCT_STAT_N_DSD_Age_Sex_ KnownNewResult 40-49, Female,	1



	Known at Entry Positive	
	PMTCT_STAT_N_DSD_Age_Sex 25-29, Female	3
	PMTCT_STAT_N_DSD_Age_Sex 30-34, Female	6
	PMTCT_STAT_N_DSD_Age_Sex 35-39, Female	2
	PMTCT_STAT_N_DSD_Age_Sex 40-49, Female	1
PMTCT_STAT_TA	PMTCT_STAT_TA Number and percentage of pregnant women with known status (includes women who were tested for HIV and received their results) (TA)	95 %
	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	18,536
	Number of new ANC and L&D clients	19,496
	By Age (Denominator): 10-14	4
	By Age (Denominator): 15-19	1,922
	By Age (Denominator): 20-24	5,425
	By Age (Denominator): 50+	0
	By known positives: <10	0
	By known positives: 10-14	0
	By known positives: 15-19	90
	By known positives: 20-24	408
	By known positives: 50+	0
	By new positives: <10	0
	By new positives: 10-14	0
	By new positives: 15-19	43
By new positives: 20-24	268	



	By new positives: 50+	0
	By new negatives: Unknown Age	0
	By new negatives: <10	0
	By new negatives: 10-14	1
	By new negatives: 15-19	1,706
	By new negatives: 20-24	4,412
	By new negatives: 50+	0
	By Age (Numerator): Unknown Age	0
	By Age (Numerator): <10	0
	By Age (Numerator): 10-14	2
	By Age (Numerator): : 15-19	1,851
	By Age (Numerator): 20-24	5,085
	By Age (Numerator): 50+	0
	PMTCT_STAT_D_TA_Age_Sex 25-29, Female	5,095
	PMTCT_STAT_D_TA_Age_Sex 30-34, Female	3,908
	PMTCT_STAT_D_TA_Age_Sex 35-39, Female	2,402
	PMTCT_STAT_D_TA_Age_Sex 40-49, Female	740
	PMTCT_STAT_N_TA_Age_Sex_K nownNewResult 25-29, Female, Known at Entry Positive	759
	PMTCT_STAT_N_TA_Age_Sex_K nownNewResult 25-29, Female, Newly Identified Negative	3,692
	PMTCT_STAT_N_TA_Age_Sex_K nownNewResult 25-29, Female, Newly Identified Positive	316
	PMTCT_STAT_N_TA_Age_Sex_K nownNewResult 30-34, Female, Known at Entry Positive	977





	PMTCT_STAT_N_TA_Age_Sex_K nownNewResult 30-34, Female, Newly Identified Negative	2,574
	PMTCT_STAT_N_TA_Age_Sex_K nownNewResult 30-34, Female, Newly Identified Positive	189
	PMTCT_STAT_N_TA_Age_Sex_K nownNewResult 35-39, Female, Known at Entry Positive	826
	PMTCT_STAT_N_TA_Age_Sex_K nownNewResult 35-39, Female, Newly Identified Negative	1,380
	PMTCT_STAT_N_TA_Age_Sex_K nownNewResult 35-39, Female, Newly Identified Positive	140
	PMTCT_STAT_N_TA_Age_Sex_K nownNewResult 40-49, Female, Known at Entry Positive	330
	PMTCT_STAT_N_TA_Age_Sex_K nownNewResult 40-49, Female, Newly Identified Negative	366
	PMTCT_STAT_N_TA_Age_Sex_K nownNewResult 40-49, Female, Newly Identified Positive	38
	PMTCT_STAT_N_TA_Age_Sex 25-29, Female	4,769
	PMTCT_STAT_N_TA_Age_Sex 30-34, Female	3,732
	PMTCT_STAT_N_TA_Age_Sex 35-39, Female	2,342
	PMTCT_STAT_N_TA_Age_Sex 40-49, Female	742
PMTCT_ART_DSD	PMTCT_ART_DSD Percentage of HIV-positive pregnant women who received ART to reduce risk of	83 %



	mother-to-child-transmission (MTCT) during pregnancy	
	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	10
	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	12
	New on ART	10
PMTCT_ART_TA	PMTCT_ART_TA Percentage of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	22 %
	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	4,100
	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	18,536
	New on ART	1,145
	Already on ART at beginning of current pregnancy	2,955
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	26,301
	By Age: 10-14	7,350



	By Age: 15-19	7,184
	By Age: 20-24	2,983
	By Age: 25-29	2,983
	By Age: 50+	553
	By circumcision technique: Surgical VMMC	26,253
	By circumcision technique: Device-based VMMC	0
	VMMC_CIRC_N_DSD_Age_Sex 30-34, Male	2,464
	VMMC_CIRC_N_DSD_Age_Sex 35-39, Male	1,702
	VMMC_CIRC_N_DSD_Age_Sex 40-49, Male	1,083
PrEP_NEW_DSD	PrEP_NEW_DSD Number of individuals who have received antiretroviral pre-exposure prophylaxis (PrEP) to prevent HIV infection in the reporting period.	n/a
	Number of individuals who have been newly enrolled on oral antiretroviral pre-exposure prophylaxis (PrEP) in the reporting period to prevent HIV infection	999
	Male 15-19	49
	Male 20-24	46
	Male 50+	9
	Female 15-19	248
	Female 20-24	444
	Female 50+	7
	FSW	200
	MSM	202
	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Female	44



	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Male	44
	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Female	20
	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Male	20
	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Female	20
	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Male	20
	PrEP_NEW_N_DSD_Age_Sex_v2 40-49, Female	14
	PrEP_NEW_N_DSD_Age_Sex_v2 40-49, Male	14
PP_PREV_DSD	PP_PREV_DSD Percentage of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period (DSD)	n/a
	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	23,564
	Age/sex: 10-14 Male	2,840
	Age/sex: 15-19 Male	1,979
	Age/sex: 20-24 Male	1,391
	Age/sex: 50+ Male	0
	Age/sex: 10-14 Female	3,900
	Age/sex: 15-19 Female	6,316
	Age/sex: 20-24 Female	6,323
	Age/sex: 50+ Female	0
	PP_PREV_N_DSD_Age_Sex_v2	247



	25-29, Female	
	PP_PREV_N_DSD_Age_Sex_v2 25-29, Male	158
	PP_PREV_N_DSD_Age_Sex_v2 30-34, Female	154
	PP_PREV_N_DSD_Age_Sex_v2 30-34, Male	111
	PP_PREV_N_DSD_Age_Sex_v2 35-39, Female	64
	PP_PREV_N_DSD_Age_Sex_v2 35-39, Male	76
	PP_PREV_N_DSD_Age_Sex_v2 40-49, Female	0
	PP_PREV_N_DSD_Age_Sex_v2 40-49, Male	5
KP_PREV_DSD	KP_PREV_DSD Percentage of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required (DSD)	n/a
	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	7,716
	By key population type: Men who have sex with men who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	300



	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	2,698
	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	4,718
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	34,360
	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	0
	Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive	0
	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	0
	Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive	0
	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	0
	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	0
	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	0
	Service Delivery Point (Facility)	0



	Inpatient: 15-19, Male, Positive	
	Service Delivery Point (Facility)	0
	Inpatient: 20-24, Female, Negative	
	Service Delivery Point (Facility)	0
	Inpatient: 20-24, Female, Positive	
	Service Delivery Point (Facility)	0
	Inpatient: 20-24, Male, Negative	
	Service Delivery Point (Facility)	0
	Inpatient: 20-24, Male, Positive	
	Service Delivery Point (Facility)	0
	Inpatient: 50+, Female, Negative	
	Service Delivery Point (Facility)	0
	Inpatient: 50+, Female, Positive	
	Service Delivery Point (Facility)	0
	Inpatient: 50+, Male, Negative	
	Service Delivery Point (Facility)	0
	Inpatient: 50+, Male, Positive	
	Service Delivery Point (Facility)	0
	Inpatient: Unknown Age, Female, Negative	
	Service Delivery Point (Facility)	0
	Inpatient: Unknown Age, Female, Positive	
	Service Delivery Point (Facility)	0
	Inpatient: Unknown Age, Male, Negative	
	Service Delivery Point (Facility)	0
	Inpatient: Unknown Age, Male, Positive	
	Service Delivery Point (Facility)	0
	Inpatient: <1, Negative	
	Service Delivery Point (Facility)	0
	Inpatient: <1, Positive	
	Service Delivery Point (Facility)	0



	Inpatient: 1-9, Negative	
	Service Delivery Point (Facility)	0
	Inpatient: 1-9, Positive	
	Service Delivery Point (Facility)	0
	Other PITC: 10-14, Female, Negative	
	Service Delivery Point (Facility)	0
	Other PITC: 10-14, Female, Positive	
	Service Delivery Point (Facility)	0
	Other PITC: 10-14, Male, Negative	
	Service Delivery Point (Facility)	0
	Other PITC: 10-14, Male, Positive	
	Service Delivery Point (Facility)	467
	Other PITC: 15-19, Female, Negative	
	Service Delivery Point (Facility)	35
	Other PITC: 15-19, Female, Positive	
	Service Delivery Point (Facility)	0
	Other PITC: 15-19, Male, Negative	
	Service Delivery Point (Facility)	0
	Other PITC: 15-19, Male, Positive	
	Service Delivery Point (Facility)	673
	Other PITC: 20-24, Female, Negative	
	Service Delivery Point (Facility)	52
	Other PITC: 20-24, Female, Positive	
	Service Delivery Point (Facility)	1,116
	Other PITC: 20-24, Male, Negative	
	Service Delivery Point (Facility)	92
	Other PITC: 20-24, Male, Positive	
	Service Delivery Point (Facility)	2,548





	Other PITC: 50+, Female, Negative	
	Service Delivery Point (Facility)	201
	Other PITC: 50+, Female, Positive	
	Service Delivery Point (Facility)	2,079
	Other PITC: 50+, Male, Negative	
	Service Delivery Point (Facility)	163
	Other PITC: 50+, Male, Positive	
	Service Delivery Point (Facility)	0
	Other PITC: Unknown Age, Female, Negative	
	Service Delivery Point (Facility)	0
	Other PITC: Unknown Age, Female, Positive	
	Service Delivery Point (Facility)	0
	Other PITC: Unknown Age, Male, Negative	
	Service Delivery Point (Facility)	0
	Other PITC: Unknown Age, Male, Positive	
	Service Delivery Point (Facility)	57
	Other PITC: <1, Negative	
	Service Delivery Point (Facility)	0
	Other PITC: <1, Positive	
	Service Delivery Point (Facility)	36
	Other PITC: 1-9, Negative	
	Service Delivery Point (Facility)	0
	Other PITC: 1-9, Positive	
	Service Delivery Point (Facility)	35
	Pediatric : <5 Negative	
	Service Delivery Point (Facility)	1
	Pediatric : <5 Positive	
	Service Delivery Point (Facility) TB: 20-24, Female, Negative	1
	Service Delivery Point (Facility) TB:	1



	20-24, Male, Negative	
	Service Delivery Point (Facility) TB: 50+, Female, Negative	21
	Service Delivery Point (Facility) TB: 50+, Female, Positive	1
	Service Delivery Point (Facility) TB: 50+, Male, Negative	15
	Service Delivery Point (Facility) VMMC: 10-14, Negative	744
	Service Delivery Point (Facility) VMMC: 15-19, Negative	575
	Service Delivery Point (Facility) VMMC: 20-24, Negative	216
	Service Delivery Point (Facility) VMMC: 50+, Negative	42
	Service Delivery Point (Facility) Index: 10-14, Female, Negative	0
	Service Delivery Point (Facility) Index: 10-14, Female, Positive	0
	Service Delivery Point (Facility) Index: 10-14, Male, Negative	0
	Service Delivery Point (Facility) Index: 10-14, Male, Positive	0
	Service Delivery Point (Facility) Index: 15-19, Female, Negative	91
	Service Delivery Point (Facility) Index: 15-19, Female, Positive	13
	Service Delivery Point (Facility) Index: 15-19, Male, Negative	0
	Service Delivery Point (Facility) Index: 15-19, Male, Positive	0
	Service Delivery Point (Facility) Index: 20-24, Female, Negative	128
	Service Delivery Point (Facility)	25



	Index: 20-24, Female, Positive	
	Service Delivery Point (Facility)	218
	Index: 20-24, Male, Negative	
	Service Delivery Point (Facility)	38
	Index: 20-24, Male, Positive	
	Service Delivery Point (Facility)	471
	Index: 50+, Female, Negative	
	Service Delivery Point (Facility)	93
	Index: 50+, Female, Positive	
	Service Delivery Point (Facility)	380
	Index: 50+, Male, Negative	
	Service Delivery Point (Facility)	76
	Index: 50+, Male, Positive	
	Service Delivery Point (Facility)	0
	Index: Unknown Age, Female, Negative	
	Service Delivery Point (Facility)	0
	Index: Unknown Age, Female, Positive	
	Service Delivery Point (Facility)	0
	Index: Unknown Age, Male, Negative	
	Service Delivery Point (Facility)	0
	Index: Unknown Age, Male, Positive	
	Service Delivery Point (Facility)	274
	Index: <1, Negative	
	Service Delivery Point (Facility)	11
	Index: <1, Positive	
	Service Delivery Point (Facility)	164
	Index: 1-9, Negative	
	Service Delivery Point (Facility)	4
	Index: 1-9, Positive	
	Service Delivery Point (Facility)	302



	ANC: 15-19, Negative	
	Service Delivery Point (Facility)	3
	ANC: 15-19, Positive	
	Service Delivery Point (Facility)	787
	ANC: 20-24, Negative	
	Service Delivery Point (Facility)	41
	ANC: 20-24, Positive	
	Service Delivery Point (Facility)	0
	VCT: 10-14, Female, Negative	
	Service Delivery Point (Facility)	0
	VCT: 10-14, Female, Positive	
	Service Delivery Point (Facility)	0
	VCT: 10-14, Male, Negative	
	Service Delivery Point (Facility)	0
	VCT: 10-14, Male, Positive	
	Service Delivery Point (Facility)	131
	VCT: 15-19, Female, Negative	
	Service Delivery Point (Facility)	6
	VCT: 15-19, Female, Positive	
	Service Delivery Point (Facility)	0
	VCT: 15-19, Male, Negative	
	Service Delivery Point (Facility)	0
	VCT: 15-19, Male, Positive	
	Service Delivery Point (Facility)	154
	VCT: 20-24, Female, Negative	
	Service Delivery Point (Facility)	6
	VCT: 20-24, Female, Positive	
	Service Delivery Point (Facility)	307
	VCT: 20-24, Male, Negative	
	Service Delivery Point (Facility)	13
	VCT: 20-24, Male, Positive	
	Service Delivery Point (Facility)	691
	VCT: 50+, Female, Negative	
	Service Delivery Point (Facility)	40



VCT: 50+, Female, Positive	
Service Delivery Point (Facility) VCT: 50+, Male, Negative	564
Service Delivery Point (Facility) VCT: 50+, Male, Positive	33
Service Delivery Point (Facility) VCT: Unknown Age, Female, Negative	0
Service Delivery Point (Facility) VCT: Unknown Age, Female, Positive	0
Service Delivery Point (Facility) VCT: Unknown Age, Male, Negative	0
Service Delivery Point (Facility) VCT: Unknown Age, Male, Positive	0
Service Delivery Point (Facility) VCT: <1, Negative	30
Service Delivery Point (Facility) VCT: <1, Positive	0
Service Delivery Point (Facility) VCT: 1-9, Negative	17
Service Delivery Point (Facility) VCT: 1-9, Positive	0
HTS_TST_N_TA_EW_Age_Sex_R esult 10-14, Female, Negative	0
HTS_TST_N_TA_EW_Age_Sex_R esult 10-14, Female, Positive	0
HTS_TST_N_TA_EW_Age_Sex_R esult 10-14, Male, Negative	0
HTS_TST_N_TA_EW_Age_Sex_R esult 10-14, Male, Positive	0
HTS_TST_N_TA_EW_Age_Sex_R esult 15-19, Female, Negative	8



	HTS_TST_N_TA_EW_Age_Sex_R esult 15-19, Female, Positive	0
	HTS_TST_N_TA_EW_Age_Sex_R esult 15-19, Male, Negative	0
	HTS_TST_N_TA_EW_Age_Sex_R esult 15-19, Male, Positive	0
	HTS_TST_N_TA_EW_Age_Sex_R esult 1-9, Unknown Sex, Negative	12
	HTS_TST_N_TA_EW_Age_Sex_R esult 1-9, Unknown Sex, Positive	0
	HTS_TST_N_TA_EW_Age_Sex_R esult <1, Unknown Sex, Negative	26
	HTS_TST_N_TA_EW_Age_Sex_R esult <1, Unknown Sex, Positive	0
	HTS_TST_N_TA_EW_Age_Sex_R esult 20-24, Female, Negative	7
	HTS_TST_N_TA_EW_Age_Sex_R esult 20-24, Female, Positive	0
	HTS_TST_N_TA_EW_Age_Sex_R esult 20-24, Male, Negative	24
	HTS_TST_N_TA_EW_Age_Sex_R esult 20-24, Male, Positive	0
	HTS_TST_N_TA_EW_Age_Sex_R esult 25-29, Female, Negative	12
	HTS_TST_N_TA_EW_Age_Sex_R esult 25-29, Female, Positive	0
	HTS_TST_N_TA_EW_Age_Sex_R esult 25-29, Male, Negative	26
	HTS_TST_N_TA_EW_Age_Sex_R esult 25-29, Male, Positive	0
	HTS_TST_N_TA_EW_Age_Sex_R esult 30-34, Female, Negative	14
	HTS_TST_N_TA_EW_Age_Sex_R esult 30-34, Female, Positive	0



	HTS_TST_N_TA_EW_Age_Sex_R esult 30-34, Male, Negative	8
	HTS_TST_N_TA_EW_Age_Sex_R esult 30-34, Male, Positive	0
	HTS_TST_N_TA_EW_Age_Sex_R esult 35-39, Female, Negative	24
	HTS_TST_N_TA_EW_Age_Sex_R esult 35-39, Female, Positive	1
	HTS_TST_N_TA_EW_Age_Sex_R esult 35-39, Male, Negative	13
	HTS_TST_N_TA_EW_Age_Sex_R esult 35-39, Male, Positive	1
	HTS_TST_N_TA_EW_Age_Sex_R esult 40-49, Female, Negative	54
	HTS_TST_N_TA_EW_Age_Sex_R esult 40-49, Female, Positive	2
	HTS_TST_N_TA_EW_Age_Sex_R esult 40-49, Male, Negative	33
	HTS_TST_N_TA_EW_Age_Sex_R esult 40-49, Male, Positive	0
	HTS_TST_N_TA_EW_Age_Sex_R esult 50+, Female, Negative	46
	HTS_TST_N_TA_EW_Age_Sex_R esult 50+, Female, Positive	1
	HTS_TST_N_TA_EW_Age_Sex_R esult 50+, Male, Negative	35
	HTS_TST_N_TA_EW_Age_Sex_R esult 50+, Male, Positive	1
	HTS_TST_N_TA_EW_Age_Sex_R esult Unknown Age, Female, Negative	0
	HTS_TST_N_TA_EW_Age_Sex_R esult Unknown Age, Female, Positive	0



HTS_TST_N_TA_EW_Age_Sex_R result Unknown Age, Male, Negative	0
HTS_TST_N_TA_EW_Age_Sex_R result Unknown Age, Male, Positive	0
HTS_TST_N_TA_Index_Age_Sex_ Result 25-29, Female, Negative	157
HTS_TST_N_TA_Index_Age_Sex_ Result 25-29, Female, Positive	31
HTS_TST_N_TA_Index_Age_Sex_ Result 25-29, Male, Negative	284
HTS_TST_N_TA_Index_Age_Sex_ Result 25-29, Male, Positive	51
HTS_TST_N_TA_Index_Age_Sex_ Result 30-34, Female, Negative	136
HTS_TST_N_TA_Index_Age_Sex_ Result 30-34, Female, Positive	26
HTS_TST_N_TA_Index_Age_Sex_ Result 30-34, Male, Negative	132
HTS_TST_N_TA_Index_Age_Sex_ Result 30-34, Male, Positive	20
HTS_TST_N_TA_Index_Age_Sex_ Result 35-39, Female, Negative	225
HTS_TST_N_TA_Index_Age_Sex_ Result 35-39, Female, Positive	44
HTS_TST_N_TA_Index_Age_Sex_ Result 35-39, Male, Negative	170
HTS_TST_N_TA_Index_Age_Sex_ Result 35-39, Male, Positive	33
HTS_TST_N_TA_Index_Age_Sex_ Result 40-49, Female, Negative	541
HTS_TST_N_TA_Index_Age_Sex_ Result 40-49, Female, Positive	106
HTS_TST_N_TA_Index_Age_Sex_ Result 40-49, Male, Negative	373





	Result 40-49, Male, Negative	
	HTS_TST_N_TA_Index_Age_Sex_	75
	Result 40-49, Male, Positive	
	HTS_TST_N_TA_Inpat_Age_Sex_	0
	Result 25-29, Female, Negative	
	HTS_TST_N_TA_Inpat_Age_Sex_	0
	Result 25-29, Female, Positive	
	HTS_TST_N_TA_Inpat_Age_Sex_	0
	Result 25-29, Male, Negative	
	HTS_TST_N_TA_Inpat_Age_Sex_	0
	Result 25-29, Male, Positive	
	HTS_TST_N_TA_Inpat_Age_Sex_	0
	Result 30-34, Female, Negative	
	HTS_TST_N_TA_Inpat_Age_Sex_	0
	Result 30-34, Female, Positive	
	HTS_TST_N_TA_Inpat_Age_Sex_	0
	Result 30-34, Male, Negative	
	HTS_TST_N_TA_Inpat_Age_Sex_	0
	Result 30-34, Male, Positive	
	HTS_TST_N_TA_Inpat_Age_Sex_	0
	Result 35-39, Female, Negative	
	HTS_TST_N_TA_Inpat_Age_Sex_	0
	Result 35-39, Female, Positive	
	HTS_TST_N_TA_Inpat_Age_Sex_	0
	Result 35-39, Male, Negative	
	HTS_TST_N_TA_Inpat_Age_Sex_	0
	Result 35-39, Male, Positive	
	HTS_TST_N_TA_Inpat_Age_Sex_	0
	Result 40-49, Female, Negative	
	HTS_TST_N_TA_Inpat_Age_Sex_	0
	Result 40-49, Female, Positive	
	HTS_TST_N_TA_Inpat_Age_Sex_	0
	Result 40-49, Male, Negative	
	HTS_TST_N_TA_Inpat_Age_Sex_	0



	Result 40-49, Male, Positive	
	HTS_TST_N_TA_MN_Age_Sex_R result <5, Unknown Sex, Negative	42
	HTS_TST_N_TA_MN_Age_Sex_R result <5, Unknown Sex, Positive	3
	HTS_TST_N_TA_OtPITC_Age_Se x_Result 25-29, Female, Negative	854
	HTS_TST_N_TA_OtPITC_Age_Se x_Result 25-29, Female, Positive	67
	HTS_TST_N_TA_OtPITC_Age_Se x_Result 25-29, Male, Negative	1,457
	HTS_TST_N_TA_OtPITC_Age_Se x_Result 25-29, Male, Positive	115
	HTS_TST_N_TA_OtPITC_Age_Se x_Result 30-34, Female, Negative	742
	HTS_TST_N_TA_OtPITC_Age_Se x_Result 30-34, Female, Positive	59
	HTS_TST_N_TA_OtPITC_Age_Se x_Result 30-34, Male, Negative	692
	HTS_TST_N_TA_OtPITC_Age_Se x_Result 30-34, Male, Positive	53
	HTS_TST_N_TA_OtPITC_Age_Se x_Result 35-39, Female, Negative	1,207
	HTS_TST_N_TA_OtPITC_Age_Se x_Result 35-39, Female, Positive	93
	HTS_TST_N_TA_OtPITC_Age_Se x_Result 35-39, Male, Negative	900
	HTS_TST_N_TA_OtPITC_Age_Se x_Result 35-39, Male, Positive	71
	HTS_TST_N_TA_OtPITC_Age_Se x_Result 40-49, Female, Negative	2,915
	HTS_TST_N_TA_OtPITC_Age_Se x_Result 40-49, Female, Positive	227
	HTS_TST_N_TA_OtPITC_Age_Se	2,020



	x_Result 40-49, Male, Negative	
	HTS_TST_N_TA_OtPITC_Age_Sex x_Result 40-49, Male, Positive	159
	HTS_TST_N_TA_PMTCT_Age_Sex x_Result 25-29, Female, Negative	679
	HTS_TST_N_TA_PMTCT_Age_Sex x_Result 25-29, Female, Positive	46
	HTS_TST_N_TA_PMTCT_Age_Sex x_Result 30-34, Female, Negative	469
	HTS_TST_N_TA_PMTCT_Age_Sex x_Result 30-34, Female, Positive	26
	HTS_TST_N_TA_PMTCT_Age_Sex x_Result 35-39, Female, Negative	247
	HTS_TST_N_TA_PMTCT_Age_Sex x_Result 35-39, Female, Positive	19
	HTS_TST_N_TA_PMTCT_Age_Sex x_Result 40-49, Female, Negative	62
	HTS_TST_N_TA_PMTCT_Age_Sex x_Result 40-49, Female, Positive	4
	HTS_TST_N_TA_STI_Age_Sex_Result <1, Unknown Sex, Negative	0
	HTS_TST_N_TA_STI_Age_Sex_Result <1, Unknown Sex, Positive	0
	HTS_TST_N_TA_STI_Age_Sex_Result 10-14, Female, Negative	0
	HTS_TST_N_TA_STI_Age_Sex_Result 10-14, Female, Positive	0
	HTS_TST_N_TA_STI_Age_Sex_Result 10-14, Male, Negative	0
	HTS_TST_N_TA_STI_Age_Sex_Result 10-14, Male, Positive	0
	HTS_TST_N_TA_STI_Age_Sex_Result 15-19, Female, Negative	9
	HTS_TST_N_TA_STI_Age_Sex_Result	0



	esult 15-19, Female, Positive	
	HTS_TST_N_TA_STI_Age_Sex_R esult 15-19, Male, Negative	0
	HTS_TST_N_TA_STI_Age_Sex_R esult 15-19, Male, Positive	0
	HTS_TST_N_TA_STI_Age_Sex_R esult 1-9, Unknown Sex, Negative	0
	HTS_TST_N_TA_STI_Age_Sex_R esult 1-9, Unknown Sex, Positive	0
	HTS_TST_N_TA_STI_Age_Sex_R esult 20-24, Female, Negative	17
	HTS_TST_N_TA_STI_Age_Sex_R esult 20-24, Female, Positive	0
	HTS_TST_N_TA_STI_Age_Sex_R esult 20-24, Male, Negative	28
	HTS_TST_N_TA_STI_Age_Sex_R esult 20-24, Male, Positive	1
	HTS_TST_N_TA_STI_Age_Sex_R esult 25-29, Female, Negative	25
	HTS_TST_N_TA_STI_Age_Sex_R esult 25-29, Female, Positive	0
	HTS_TST_N_TA_STI_Age_Sex_R esult 25-29, Male, Negative	38
	HTS_TST_N_TA_STI_Age_Sex_R esult 25-29, Male, Positive	5
	HTS_TST_N_TA_STI_Age_Sex_R esult 30-34, Female, Negative	23
	HTS_TST_N_TA_STI_Age_Sex_R esult 30-34, Female, Positive	0
	HTS_TST_N_TA_STI_Age_Sex_R esult 30-34, Male, Negative	17
	HTS_TST_N_TA_STI_Age_Sex_R esult 30-34, Male, Positive	1
	HTS_TST_N_TA_STI_Age_Sex_R	31



	esult 35-39, Female, Negative	
	HTS_TST_N_TA_STI_Age_Sex_R esult 35-39, Female, Positive	2
	HTS_TST_N_TA_STI_Age_Sex_R esult 35-39, Male, Negative	26
	HTS_TST_N_TA_STI_Age_Sex_R esult 35-39, Male, Positive	1
	HTS_TST_N_TA_STI_Age_Sex_R esult 40-49, Female, Negative	79
	HTS_TST_N_TA_STI_Age_Sex_R esult 40-49, Female, Positive	12
	HTS_TST_N_TA_STI_Age_Sex_R esult 40-49, Male, Negative	54
	HTS_TST_N_TA_STI_Age_Sex_R esult 40-49, Male, Positive	5
	HTS_TST_N_TA_STI_Age_Sex_R esult 50+, Female, Negative	72
	HTS_TST_N_TA_STI_Age_Sex_R esult 50+, Female, Positive	8
	HTS_TST_N_TA_STI_Age_Sex_R esult 50+, Male, Negative	55
	HTS_TST_N_TA_STI_Age_Sex_R esult 50+, Male, Positive	6
	HTS_TST_N_TA_STI_Age_Sex_R esult Unknown Age, Female, Negative	0
	HTS_TST_N_TA_STI_Age_Sex_R esult Unknown Age, Female, Positive	0
	HTS_TST_N_TA_STI_Age_Sex_R esult Unknown Age, Male, Negative	0
	HTS_TST_N_TA_STI_Age_Sex_R esult Unknown Age, Male, Positive	0



HTS_TST_N_TA_TBC_Age_Sex_ Result 25-29, Female, Negative	2
HTS_TST_N_TA_TBC_Age_Sex_ Result 25-29, Male, Negative	2
HTS_TST_N_TA_TBC_Age_Sex_ Result 30-34, Female, Negative	2
HTS_TST_N_TA_TBC_Age_Sex_ Result 30-34, Male, Negative	3
HTS_TST_N_TA_TBC_Age_Sex_ Result 35-39, Female, Negative	10
HTS_TST_N_TA_TBC_Age_Sex_ Result 35-39, Male, Negative	4
HTS_TST_N_TA_TBC_Age_Sex_ Result 40-49, Female, Negative	30
HTS_TST_N_TA_TBC_Age_Sex_ Result 40-49, Female, Positive	1
HTS_TST_N_TA_TBC_Age_Sex_ Result 40-49, Male, Negative	13
HTS_TST_N_TA_VCT_Age_Sex_ Result 25-29, Female, Negative	208
HTS_TST_N_TA_VCT_Age_Sex_ Result 25-29, Female, Positive	8
HTS_TST_N_TA_VCT_Age_Sex_ Result 25-29, Male, Negative	389
HTS_TST_N_TA_VCT_Age_Sex_ Result 25-29, Male, Positive	20
HTS_TST_N_TA_VCT_Age_Sex_ Result 30-34, Female, Negative	202
HTS_TST_N_TA_VCT_Age_Sex_ Result 30-34, Female, Positive	10
HTS_TST_N_TA_VCT_Age_Sex_ Result 30-34, Male, Negative	144
HTS_TST_N_TA_VCT_Age_Sex_ Result 30-34, Male, Positive	5



	HTS_TST_N_TA_VCT_Age_Sex_ Result 35-39, Female, Negative	327
	HTS_TST_N_TA_VCT_Age_Sex_ Result 35-39, Female, Positive	21
	HTS_TST_N_TA_VCT_Age_Sex_ Result 35-39, Male, Negative	204
	HTS_TST_N_TA_VCT_Age_Sex_ Result 35-39, Male, Positive	11
	HTS_TST_N_TA_VCT_Age_Sex_ Result 40-49, Female, Negative	793
	HTS_TST_N_TA_VCT_Age_Sex_ Result 40-49, Female, Positive	46
	HTS_TST_N_TA_VCT_Age_Sex_ Result 40-49, Male, Negative	548
	HTS_TST_N_TA_VCT_Age_Sex_ Result 40-49, Male, Positive	33
	HTS_TST_N_TA_VMMC_Age_Sex_ Result 25-29, Male, Negative	216
	HTS_TST_N_TA_VMMC_Age_Sex_ Result 30-34, Male, Negative	150
	HTS_TST_N_TA_VMMC_Age_Sex_ Result 30-34, Male, Positive	1
	HTS_TST_N_TA_VMMC_Age_Sex_ Result 35-39, Male, Negative	84
	HTS_TST_N_TA_VMMC_Age_Sex_ Result 35-39, Male, Positive	1
	HTS_TST_N_TA_VMMC_Age_Sex_ Result 40-49, Male, Negative	42
HTS_SELF_TA	HTS_SELF_N_TA	0
	HTS_SELF_N_TA_Age_Sex_HIVS elfTest 10-14, Male, Unassisted	0
	HTS_SELF_N_TA_Age_Sex_HIVS elfTest 15-19, Female, Unassisted	0
	HTS_SELF_N_TA_Age_Sex_HIVS	0



	elfTest 15-19, Male, Unassisted	
	HTS_SELF_N_TA_Age_Sex_HIVS elfTest 20-24, Female, Unassisted	0
	HTS_SELF_N_TA_Age_Sex_HIVS elfTest 20-24, Male, Unassisted	0
	HTS_SELF_N_TA_Age_Sex_HIVS elfTest 25-29, Female, Unassisted	0
	HTS_SELF_N_TA_Age_Sex_HIVS elfTest 25-29, Male, Unassisted	0
	HTS_SELF_N_TA_Age_Sex_HIVS elfTest 30-34, Female, Unassisted	0
	HTS_SELF_N_TA_Age_Sex_HIVS elfTest 30-34, Male, Unassisted	0
	HTS_SELF_N_TA_Age_Sex_HIVS elfTest 35-39, Female, Unassisted	0
	HTS_SELF_N_TA_Age_Sex_HIVS elfTest 35-39, Male, Unassisted	0
	HTS_SELF_N_TA_Age_Sex_HIVS elfTest 40-49, Female, Unassisted	0
	HTS_SELF_N_TA_Age_Sex_HIVS elfTest 40-49, Male, Unassisted	0
	HTS_SELF_N_TA_Age_Sex_HIVS elfTest 50+, Female, Unassisted	0
	HTS_SELF_N_TA_Age_Sex_HIVS elfTest 50+, Male, Unassisted	0
	HTS_SELF_N_TA_Age_Sex_HIVS elfTest Unknown Age, Male, Unassisted	0
	HTS_SELF_N_TA_HIVSelfTest Unassisted	0
	HTS_SELF_N_TA_HIVSelfTestUs er Unassisted - Self	0
	HTS_SELF_N_TA_HIVSelfTestUs er Unassisted - Sex Partner	0





TB_STAT_TA	TB_STAT_TA Percentage of registered new and relapsed TB cases with documented HIV status.	100 %
	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	2,540
	Total number of registered new and relapsed TB cases, during the reporting period.	2,540
	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	1,132
	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	1,409
	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,409
	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,132
HTS_SELF_DSD	HTS_SELF_N_DSD	30,602
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 10-14, Male, Directly-Assisted	0
	HTS_SELF_N_DSD_Age_Sex_HI	0



	VSelfTest 15-19, Female, Directly-Assisted	
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 15-19, Female, Unassisted	312
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 15-19, Male, Directly-Assisted	0
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 15-19, Male, Unassisted	312
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 20-24, Female, Directly-Assisted	0
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 20-24, Female, Unassisted	779
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 20-24, Male, Directly-Assisted	0
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 20-24, Male, Unassisted	782
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 25-29, Female, Directly-Assisted	0
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 25-29, Female, Unassisted	1,050
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 25-29, Male, Directly-Assisted	0
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 25-29, Male, Unassisted	1,051
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 30-34, Female, Directly-Assisted	0



HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 30-34, Female, Unassisted	1,280
HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 30-34, Male, Directly-Assisted	0
HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 30-34, Male, Unassisted	1,279
HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 35-39, Female, Directly-Assisted	0
HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 35-39, Female, Unassisted	2,853
HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 35-39, Male, Directly-Assisted	500
HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 35-39, Male, Unassisted	2,853
HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 40-49, Female, Directly-Assisted	0
HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 40-49, Female, Unassisted	4,806
HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 40-49, Male, Directly-Assisted	530
HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 40-49, Male, Unassisted	4,804
HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 50+, Female, Directly-Assisted	0
HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 50+, Female, Unassisted	3,456



	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 50+, Male, Directly-Assisted	500
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 50+, Male, Unassisted	3,456
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest Unknown Age, Male, Directly-Assisted	0
	HTS_SELF_N_DSD_HIVSelfTest Directly-Assisted	1,530
	HTS_SELF_N_DSD_HIVSelfTest Unassisted	29,072
	HTS_SELF_N_DSD_HIVSelfTestU ser Unassisted - Self	5,815
	HTS_SELF_N_DSD_HIVSelfTestU ser Unassisted - Sex Partner	23,086
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	488,496
	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	265
	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	16
	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	18
	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	4
	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	609
	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	41
	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	568



	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	44
	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	2,949
	Service Delivery Point (Facility) Inpatient: 50+, Female, Positive	204
	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	2,569
	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	173
	Service Delivery Point (Facility) Inpatient: <1, Negative	611
	Service Delivery Point (Facility) Inpatient: <1, Positive	46
	Service Delivery Point (Facility) Inpatient: 1-9, Negative	276
	Service Delivery Point (Facility) Inpatient: 1-9, Positive	23
	Service Delivery Point (Community) Mobile Testing: 10-14, Female, Negative	31
	Service Delivery Point (Community) Mobile Testing: 10-14, Female, Positive	1
	Service Delivery Point (Community) Mobile Testing: 10-14, Male, Negative	2
	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Negative	3,013
	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Positive	79
	Service Delivery Point (Community)	1,072



	Mobile Testing: 15-19, Male, Negative	
	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Positive	133
	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Negative	3,451
	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Positive	118
	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Negative	1,352
	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Positive	192
	Service Delivery Point (Community) Mobile Testing: 50+, Female, Negative	1,651
	Service Delivery Point (Community) Mobile Testing: 50+, Female, Positive	122
	Service Delivery Point (Community) Mobile Testing: 50+, Male, Negative	1,947
	Service Delivery Point (Community) Mobile Testing: 50+, Male, Positive	91
	Service Delivery Point (Community) Mobile Testing: <1, Negative	85
	Service Delivery Point (Community) Mobile Testing: <1, Positive	3
	Service Delivery Point (Community) Mobile Testing: 1-9, Negative	24
	Service Delivery Point (Facility)	2,215



	Other PITC: 15-19, Female, Negative	
	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	172
	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	6,315
	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	484
	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	5,149
	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	391
	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	21,174
	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	1,667
	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	18,537
	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	1,456
	Service Delivery Point (Facility) Other PITC: <1, Negative	530
	Service Delivery Point (Facility) Other PITC: <1, Positive	20
	Service Delivery Point (Facility) Other PITC: 1-9, Negative	239
	Service Delivery Point (Facility) Other PITC: 1-9, Positive	6
	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	356



	Service Delivery Point (Community) Other: 10-14, Female, Positive	14
	Service Delivery Point (Community) Other: 10-14, Male, Negative	349
	Service Delivery Point (Community) Other: 10-14, Male, Positive	12
	Service Delivery Point (Community) Other: 15-19, Female, Negative	9,372
	Service Delivery Point (Community) Other: 15-19, Female, Positive	54
	Service Delivery Point (Community) Other: 15-19, Male, Negative	1,923
	Service Delivery Point (Community) Other: 15-19, Male, Positive	98
	Service Delivery Point (Community) Other: 20-24, Female, Negative	10,242
	Service Delivery Point (Community) Other: 20-24, Female, Positive	102
	Service Delivery Point (Community) Other: 20-24, Male, Negative	2,368
	Service Delivery Point (Community) Other: 20-24, Male, Positive	128
	Service Delivery Point (Community) Other: 50+, Female, Negative	4,461
	Service Delivery Point (Community) Other: 50+, Female, Positive	290
	Service Delivery Point (Community) Other: 50+, Male, Negative	5,498
	Service Delivery Point (Community) Other: 50+, Male, Positive	382
	Service Delivery Point (Community) Other: <1, Negative	149
	Service Delivery Point (Community) Other: <1, Positive	12





Service Delivery Point (Community) Other: 1-9, Negative	62
Service Delivery Point (Community) Other: 1-9, Positive	9
Service Delivery Point (Facility) Pediatric : <5 Negative	278
Service Delivery Point (Facility) Pediatric : <5 Positive	22
Service Delivery Point (Facility) TB: 15-19, Female, Negative	7
Service Delivery Point (Facility) TB: 20-24, Female, Negative	30
Service Delivery Point (Facility) TB: 20-24, Male, Negative	14
Service Delivery Point (Facility) TB: 50+, Female, Negative	127
Service Delivery Point (Facility) TB: 50+, Female, Positive	22
Service Delivery Point (Facility) TB: 50+, Male, Negative	89
Service Delivery Point (Facility) TB: 50+, Male, Positive	7
Service Delivery Point (Facility) VMMC: 10-14, Negative	8,378
Service Delivery Point (Facility) VMMC: 10-14, Positive	32
Service Delivery Point (Facility) VMMC: 15-19, Negative	7,079
Service Delivery Point (Facility) VMMC: 15-19, Positive	25
Service Delivery Point (Facility) VMMC: 1-9, Positive	1
Service Delivery Point (Facility) VMMC: 20-24, Negative	2,455



	Service Delivery Point (Facility) VMMC: 20-24, Positive	10
	Service Delivery Point (Facility) VMMC: 50+, Negative	477
	Service Delivery Point (Facility) VMMC: 50+, Positive	2
	Service Delivery Point (Facility) Index: 15-19, Female, Negative	420
	Service Delivery Point (Facility) Index: 15-19, Female, Positive	74
	Service Delivery Point (Facility) Index: 20-24, Female, Negative	1,246
	Service Delivery Point (Facility) Index: 20-24, Female, Positive	228
	Service Delivery Point (Facility) Index: 20-24, Male, Negative	990
	Service Delivery Point (Facility) Index: 20-24, Male, Positive	179
	Service Delivery Point (Facility) Index: 50+, Female, Negative	3,895
	Service Delivery Point (Facility) Index: 50+, Female, Positive	760
	Service Delivery Point (Facility) Index: 50+, Male, Negative	3,387
	Service Delivery Point (Facility) Index: 50+, Male, Positive	671
	Service Delivery Point (Facility) Index: <1, Negative	2,713
	Service Delivery Point (Facility) Index: <1, Positive	141
	Service Delivery Point (Facility) Index: 1-9, Negative	1,196
	Service Delivery Point (Facility) Index: 1-9, Positive	64



	By Key Population: FSW, Negative	2,530
	By Key Population: FSW, Positive	446
	By Key Population: MSM, Negative	1,766
	By Key Population: MSM, Positive	313
	Service Delivery Point (Community) Index Mod: 10-14, Female, Negative	88
	Service Delivery Point (Community) Index Mod: 10-14, Female, Positive	1
	Service Delivery Point (Community) Index Mod: 10-14, Male, Negative	58
	Service Delivery Point (Community) Index Mod: 15-19, Female, Negative	1,249
	Service Delivery Point (Community) Index Mod: 15-19, Female, Positive	42
	Service Delivery Point (Community) Index Mod: 15-19, Male, Negative	481
	Service Delivery Point (Community) Index Mod: 15-19, Male, Positive	31
	Service Delivery Point (Community) Index Mod: 20-24, Female, Negative	1,399
	Service Delivery Point (Community) Index Mod: 20-24, Female, Positive	148
	Service Delivery Point (Community) Index Mod: 20-24, Male, Negative	589
	Service Delivery Point (Community) Index Mod: 20-24, Male, Positive	149
	Service Delivery Point (Community) Index Mod: 50+, Female, Negative	824
	Service Delivery Point (Community) Index Mod: 50+, Female, Positive	272
	Service Delivery Point (Community)	845



	Index Mod: 50+, Male, Negative	
	Service Delivery Point (Community) Index Mod: 50+, Male, Positive	262
	Service Delivery Point (Community) Index Mod: <1, Negative	363
	Service Delivery Point (Community) Index Mod: <1, Positive	36
	Service Delivery Point (Community) Index Mod: 1-9, Negative	268
	Service Delivery Point (Community) Index Mod: 1-9, Positive	5
	Service Delivery Point (Facility) ANC: 15-19, Negative	1,401
	Service Delivery Point (Facility) ANC: 15-19, Positive	42
	Service Delivery Point (Facility) ANC: 20-24, Negative	3,612
	Service Delivery Point (Facility) ANC: 20-24, Positive	222
	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	425
	Service Delivery Point (Facility) VCT: 15-19, Female, Positive	21
	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	1,148
	Service Delivery Point (Facility) VCT: 15-19, Male, Positive	24
	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	1,351
	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	81
	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	2,088
	Service Delivery Point (Facility)	89



	VCT: 20-24, Male, Positive	
	Service Delivery Point (Facility) VCT: 50+, Female, Negative	5,735
	Service Delivery Point (Facility) VCT: 50+, Female, Positive	333
	Service Delivery Point (Facility) VCT: 50+, Male, Negative	5,129
	Service Delivery Point (Facility) VCT: 50+, Male, Positive	294
	Service Delivery Point (Facility) VCT: <1, Negative	276
	Service Delivery Point (Facility) VCT: <1, Positive	8
	Service Delivery Point (Facility) VCT: 1-9, Negative	128
	Service Delivery Point (Facility) VCT: 1-9, Positive	1
	Service Delivery Point (Community) VCT Mod: 10-14, Female, Negative	6
	Service Delivery Point (Community) VCT Mod: 10-14, Female, Positive	1
	Service Delivery Point (Community) VCT Mod: 10-14, Male, Negative	6
	Service Delivery Point (Community) VCT Mod: 10-14, Male, Positive	1
	Service Delivery Point (Community) VCT Mod: 15-19, Female, Negative	1,235
	Service Delivery Point (Community) VCT Mod: 15-19, Female, Positive	15
	Service Delivery Point (Community) VCT Mod: 15-19, Male, Negative	266
	Service Delivery Point (Community) VCT Mod: 15-19, Male, Positive	9
	Service Delivery Point (Community)	1,382



VCT Mod: 20-24, Female, Negative	
Service Delivery Point (Community) VCT Mod: 20-24, Female, Positive	9
Service Delivery Point (Community) VCT Mod: 20-24, Male, Negative	314
Service Delivery Point (Community) VCT Mod: 20-24, Male, Positive	18
Service Delivery Point (Community) VCT Mod: 50+, Female, Negative	253
Service Delivery Point (Community) VCT Mod: 50+, Female, Positive	23
Service Delivery Point (Community) VCT Mod: 50+, Male, Negative	148
Service Delivery Point (Community) VCT Mod: 50+, Male, Positive	28
Service Delivery Point (Community) VCT Mod: <1, Negative	37
Service Delivery Point (Community) VCT Mod: <1, Positive	4
Service Delivery Point (Community) VCT Mod: 1-9, Negative	37
HTS_TST_N_DSD_EW_Age_Sex_ Result <1, Unknown Sex, Negative	215
HTS_TST_N_DSD_EW_Age_Sex_ Result <1, Unknown Sex, Positive	12
HTS_TST_N_DSD_EW_Age_Sex_ Result 15-19, Female, Negative	34
HTS_TST_N_DSD_EW_Age_Sex_ Result 15-19, Female, Positive	3
HTS_TST_N_DSD_EW_Age_Sex_ Result 1-9, Unknown Sex, Negative	95
HTS_TST_N_DSD_EW_Age_Sex_ Result 1-9, Unknown Sex, Positive	1
HTS_TST_N_DSD_EW_Age_Sex_	107



	Result 20-24, Female, Negative	
	HTS_TST_N_DSD_EW_Age_Sex_ Result 20-24, Female, Positive	6
	HTS_TST_N_DSD_EW_Age_Sex_ Result 20-24, Male, Negative	93
	HTS_TST_N_DSD_EW_Age_Sex_ Result 20-24, Male, Positive	8
	HTS_TST_N_DSD_EW_Age_Sex_ Result 25-29, Female, Negative	137
	HTS_TST_N_DSD_EW_Age_Sex_ Result 25-29, Female, Positive	7
	HTS_TST_N_DSD_EW_Age_Sex_ Result 25-29, Male, Negative	132
	HTS_TST_N_DSD_EW_Age_Sex_ Result 25-29, Male, Positive	10
	HTS_TST_N_DSD_EW_Age_Sex_ Result 30-34, Female, Negative	112
	HTS_TST_N_DSD_EW_Age_Sex_ Result 30-34, Female, Positive	6
	HTS_TST_N_DSD_EW_Age_Sex_ Result 30-34, Male, Negative	97
	HTS_TST_N_DSD_EW_Age_Sex_ Result 30-34, Male, Positive	8
	HTS_TST_N_DSD_EW_Age_Sex_ Result 35-39, Female, Negative	180
	HTS_TST_N_DSD_EW_Age_Sex_ Result 35-39, Female, Positive	22
	HTS_TST_N_DSD_EW_Age_Sex_ Result 35-39, Male, Negative	135
	HTS_TST_N_DSD_EW_Age_Sex_ Result 35-39, Male, Positive	10
	HTS_TST_N_DSD_EW_Age_Sex_ Result 40-49, Female, Negative	436
	HTS_TST_N_DSD_EW_Age_Sex_	53



	Result 40-49, Female, Positive	
	HTS_TST_N_DSD_EW_Age_Sex_	316
	Result 40-49, Male, Negative	
	HTS_TST_N_DSD_EW_Age_Sex_	36
	Result 40-49, Male, Positive	
	HTS_TST_N_DSD_EW_Age_Sex_	384
	Result 50+, Female, Negative	
	HTS_TST_N_DSD_EW_Age_Sex_	45
	Result 50+, Female, Positive	
	HTS_TST_N_DSD_EW_Age_Sex_	334
	Result 50+, Male, Negative	
	HTS_TST_N_DSD_EW_Age_Sex_	39
	Result 50+, Male, Positive	
	HTS_TST_N_DSD_Index_Age_Sex_	1,489
	Result 25-29, Female, Negative	
	HTS_TST_N_DSD_Index_Age_Sex_	276
	Result 25-29, Female, Positive	
	HTS_TST_N_DSD_Index_Age_Sex_	1,435
	Result 25-29, Male, Negative	
	HTS_TST_N_DSD_Index_Age_Sex_	249
	Result 25-29, Male, Positive	
	HTS_TST_N_DSD_Index_Age_Sex_	1,163
	Result 30-34, Female, Negative	
	HTS_TST_N_DSD_Index_Age_Sex_	235
	Result 30-34, Female, Positive	
	HTS_TST_N_DSD_Index_Age_Sex_	1,217
	Result 30-34, Male, Negative	
	HTS_TST_N_DSD_Index_Age_Sex_	200
	Result 30-34, Male, Positive	
	HTS_TST_N_DSD_Index_Age_Sex_	1,848
	Result 35-39, Female, Negative	
	HTS_TST_N_DSD_Index_Age_Sex_	361
	Result 35-39, Female, Positive	
	HTS_TST_N_DSD_Index_Age_Sex_	1,557





	x_Result 35-39, Male, Negative	
	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Positive	270
	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Negative	4,455
	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Positive	870
	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Negative	3,211
	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Positive	633
	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Negative	845
	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Positive	55
	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Negative	731
	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Positive	54
	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Negative	855
	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Positive	55
	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Negative	423
	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Positive	33
	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Negative	1,393
	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Positive	95
	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Negative	713
	HTS_TST_N_DSD_Inpat_Age_Sex	62



	_Result 35-39, Male, Positive	
	HTS_TST_N_DSD_Inpat_Age_Sex _Result 40-49, Female, Negative	3,372
	HTS_TST_N_DSD_Inpat_Age_Sex _Result 40-49, Female, Positive	231
	HTS_TST_N_DSD_Inpat_Age_Sex _Result 40-49, Male, Negative	2,408
	HTS_TST_N_DSD_Inpat_Age_Sex _Result 40-49, Male, Positive	175
	HTS_TST_N_DSD_MbMod_Age_ Sex_Result 25-29, Female, Negative	2,997
	HTS_TST_N_DSD_MbMod_Age_ Sex_Result 25-29, Female, Positive	219
	HTS_TST_N_DSD_MbMod_Age_ Sex_Result 25-29, Male, Negative	3,363
	HTS_TST_N_DSD_MbMod_Age_ Sex_Result 25-29, Male, Positive	223
	HTS_TST_N_DSD_MbMod_Age_ Sex_Result 30-34, Female, Negative	3,190
	HTS_TST_N_DSD_MbMod_Age_ Sex_Result 30-34, Female, Positive	221
	HTS_TST_N_DSD_MbMod_Age_ Sex_Result 30-34, Male, Negative	3,973
	HTS_TST_N_DSD_MbMod_Age_ Sex_Result 30-34, Male, Positive	197
	HTS_TST_N_DSD_MbMod_Age_ Sex_Result 35-39, Female, Negative	2,649
	HTS_TST_N_DSD_MbMod_Age_ Sex_Result 35-39, Female,	233



	Positive	
	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Male, Negative	3,231
	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Male, Positive	217
	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Female, Negative	2,846
	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Female, Positive	266
	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Male, Negative	3,011
	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Male, Positive	127
	HTS_TST_N_DSD_MN_Age_Sex_Result <5, Unknown Sex, Negative	275
	HTS_TST_N_DSD_MN_Age_Sex_Result <5, Unknown Sex, Positive	42
	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Negative	751
	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Positive	298
	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Negative	834
	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Positive	354
	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Negative	842
	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Positive	289



	Positive	
	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Negative	1,011
	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Positive	393
	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Female, Negative	1,602
	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Female, Positive	393
	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Negative	1,833
	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Positive	344
	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Female, Negative	1,276
	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Female, Positive	337
	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Negative	1,141
	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Positive	329
	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Negative	7,684
	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Positive	592
	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Negative	7,367
	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Positive	560



	Sex_Result 25-29, Male, Positive	
	HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 30-34, Female, Negative	6,155
	HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 30-34, Female, Positive	483
	HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 30-34, Male, Negative	6,133
	HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 30-34, Male, Positive	459
	HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 35-39, Female, Negative	10,010
	HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 35-39, Female, Positive	785
	HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 35-39, Male, Negative	8,042
	HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 35-39, Male, Positive	612
	HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 40-49, Female, Negative	24,227
	HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 40-49, Female, Positive	1,909
	HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 40-49, Male, Negative	17,494
	HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 40-49, Male, Positive	1,379
	HTS_TST_N_DSD_OtrMod_Age_ Sex_Result 25-29, Female, Negative	8,928



HTS_TST_N_DSD_OtrMod_Age_Sex_Result 25-29, Female, Positive	452
HTS_TST_N_DSD_OtrMod_Age_Sex_Result 25-29, Male, Negative	10,157
HTS_TST_N_DSD_OtrMod_Age_Sex_Result 25-29, Male, Positive	562
HTS_TST_N_DSD_OtrMod_Age_Sex_Result 30-34, Female, Negative	10,728
HTS_TST_N_DSD_OtrMod_Age_Sex_Result 30-34, Female, Positive	501
HTS_TST_N_DSD_OtrMod_Age_Sex_Result 30-34, Male, Negative	12,639
HTS_TST_N_DSD_OtrMod_Age_Sex_Result 30-34, Male, Positive	647
HTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Female, Negative	8,139
HTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Female, Positive	616
HTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Male, Negative	9,524
HTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Male, Positive	640
HTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Female, Negative	8,516
HTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Female, Positive	596
HTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Male, Negative	9,530



HTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Male, Positive	735
HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Negative	2,987
HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Positive	267
HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Negative	2,094
HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Positive	152
HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Negative	1,125
HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Positive	116
HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Negative	298
HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Positive	32
HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Female, Negative	54
HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Female, Positive	3
HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Female, Negative	165
HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Female, Positive	17
HTS_TST_N_DSD_STI_Age_Sex_	130



	Result 20-24, Male, Negative	
	HTS_TST_N_DSD_STI_Age_Sex_ Result 20-24, Male, Positive	9
	HTS_TST_N_DSD_STI_Age_Sex_ Result 25-29, Female, Negative	204
	HTS_TST_N_DSD_STI_Age_Sex_ Result 25-29, Female, Positive	24
	HTS_TST_N_DSD_STI_Age_Sex_ Result 25-29, Male, Negative	191
	HTS_TST_N_DSD_STI_Age_Sex_ Result 25-29, Male, Positive	13
	HTS_TST_N_DSD_STI_Age_Sex_ Result 30-34, Female, Negative	173
	HTS_TST_N_DSD_STI_Age_Sex_ Result 30-34, Female, Positive	23
	HTS_TST_N_DSD_STI_Age_Sex_ Result 30-34, Male, Negative	160
	HTS_TST_N_DSD_STI_Age_Sex_ Result 30-34, Male, Positive	11
	HTS_TST_N_DSD_STI_Age_Sex_ Result 35-39, Female, Negative	275
	HTS_TST_N_DSD_STI_Age_Sex_ Result 35-39, Female, Positive	46
	HTS_TST_N_DSD_STI_Age_Sex_ Result 35-39, Male, Negative	207
	HTS_TST_N_DSD_STI_Age_Sex_ Result 35-39, Male, Positive	29
	HTS_TST_N_DSD_STI_Age_Sex_ Result 40-49, Female, Negative	673
	HTS_TST_N_DSD_STI_Age_Sex_ Result 40-49, Female, Positive	121
	HTS_TST_N_DSD_STI_Age_Sex_ Result 40-49, Male, Negative	489
	HTS_TST_N_DSD_STI_Age_Sex_	87





	Result 40-49, Male, Positive	
	HTS_TST_N_DSD_STI_Age_Sex_ Result 50+, Female, Negative	584
	HTS_TST_N_DSD_STI_Age_Sex_ Result 50+, Female, Positive	100
	HTS_TST_N_DSD_STI_Age_Sex_ Result 50+, Male, Negative	513
	HTS_TST_N_DSD_STI_Age_Sex_ Result 50+, Male, Positive	94
	HTS_TST_N_DSD_TBC_Age_Sex_ _Result 25-29, Female, Negative	37
	HTS_TST_N_DSD_TBC_Age_Sex_ _Result 25-29, Female, Positive	1
	HTS_TST_N_DSD_TBC_Age_Sex_ _Result 25-29, Male, Negative	23
	HTS_TST_N_DSD_TBC_Age_Sex_ _Result 25-29, Male, Positive	2
	HTS_TST_N_DSD_TBC_Age_Sex_ _Result 30-34, Female, Negative	33
	HTS_TST_N_DSD_TBC_Age_Sex_ _Result 30-34, Female, Positive	1
	HTS_TST_N_DSD_TBC_Age_Sex_ _Result 30-34, Male, Negative	25
	HTS_TST_N_DSD_TBC_Age_Sex_ _Result 30-34, Male, Positive	2
	HTS_TST_N_DSD_TBC_Age_Sex_ _Result 35-39, Female, Negative	59
	HTS_TST_N_DSD_TBC_Age_Sex_ _Result 35-39, Female, Positive	4
	HTS_TST_N_DSD_TBC_Age_Sex_ _Result 35-39, Male, Negative	43
	HTS_TST_N_DSD_TBC_Age_Sex_ _Result 40-49, Female, Negative	148
	HTS_TST_N_DSD_TBC_Age_Sex	23



	_Result 40-49, Female, Positive	
	HTS_TST_N_DSD_TBC_Age_Sex _Result 40-49, Male, Negative	87
	HTS_TST_N_DSD_TBC_Age_Sex _Result 40-49, Male, Positive	7
	HTS_TST_N_DSD_VCT_Age_Sex _Result 25-29, Female, Negative	1,780
	HTS_TST_N_DSD_VCT_Age_Sex _Result 25-29, Female, Positive	103
	HTS_TST_N_DSD_VCT_Age_Sex _Result 25-29, Male, Negative	2,467
	HTS_TST_N_DSD_VCT_Age_Sex _Result 25-29, Male, Positive	115
	HTS_TST_N_DSD_VCT_Age_Sex _Result 30-34, Female, Negative	1,670
	HTS_TST_N_DSD_VCT_Age_Sex _Result 30-34, Female, Positive	98
	HTS_TST_N_DSD_VCT_Age_Sex _Result 30-34, Male, Negative	2,038
	HTS_TST_N_DSD_VCT_Age_Sex _Result 30-34, Male, Positive	84
	HTS_TST_N_DSD_VCT_Age_Sex _Result 35-39, Female, Negative	2,713
	HTS_TST_N_DSD_VCT_Age_Sex _Result 35-39, Female, Positive	158
	HTS_TST_N_DSD_VCT_Age_Sex _Result 35-39, Male, Negative	2,414
	HTS_TST_N_DSD_VCT_Age_Sex _Result 35-39, Male, Positive	116
	HTS_TST_N_DSD_VCT_Age_Sex _Result 40-49, Female, Negative	6,565
	HTS_TST_N_DSD_VCT_Age_Sex _Result 40-49, Female, Positive	384
	HTS_TST_N_DSD_VCT_Age_Sex	5,201



	_Result 40-49, Male, Negative	
	HTS_TST_N_DSD_VCT_Age_Sex _Result 40-49, Male, Positive	284
	HTS_TST_N_DSD_VCTMod_Age_ Sex_Result 25-29, Female, Negative	1,538
	HTS_TST_N_DSD_VCTMod_Age_ Sex_Result 25-29, Female, Positive	65
	HTS_TST_N_DSD_VCTMod_Age_ Sex_Result 25-29, Male, Negative	1,624
	HTS_TST_N_DSD_VCTMod_Age_ Sex_Result 25-29, Male, Positive	62
	HTS_TST_N_DSD_VCTMod_Age_ Sex_Result 30-34, Female, Negative	1,484
	HTS_TST_N_DSD_VCTMod_Age_ Sex_Result 30-34, Female, Positive	76
	HTS_TST_N_DSD_VCTMod_Age_ Sex_Result 30-34, Male, Negative	1,390
	HTS_TST_N_DSD_VCTMod_Age_ Sex_Result 30-34, Male, Positive	81
	HTS_TST_N_DSD_VCTMod_Age_ Sex_Result 35-39, Female, Negative	1,050
	HTS_TST_N_DSD_VCTMod_Age_ Sex_Result 35-39, Female, Positive	62
	HTS_TST_N_DSD_VCTMod_Age_ Sex_Result 35-39, Male, Negative	1,160
	HTS_TST_N_DSD_VCTMod_Age_ Sex_Result 35-39, Male, Positive	68
	HTS_TST_N_DSD_VCTMod_Age_ Sex_Result 35-39, Male, Positive	685



	Sex_Result 40-49, Female, Negative	
	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 40-49, Female, Positive	70
	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 40-49, Male, Negative	747
	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 40-49, Male, Positive	56
	HTS_TST_N_DSD_VMMC_Age_Sex_Result 25-29, Male, Negative	2,434
	HTS_TST_N_DSD_VMMC_Age_Sex_Result 25-29, Male, Positive	11
	HTS_TST_N_DSD_VMMC_Age_Sex_Result 30-34, Male, Negative	1,701
	HTS_TST_N_DSD_VMMC_Age_Sex_Result 30-34, Male, Positive	11
	HTS_TST_N_DSD_VMMC_Age_Sex_Result 35-39, Male, Negative	969
	HTS_TST_N_DSD_VMMC_Age_Sex_Result 35-39, Male, Positive	9
	HTS_TST_N_DSD_VMMC_Age_Sex_Result 40-49, Male, Negative	491
	HTS_TST_N_DSD_VMMC_Age_Sex_Result 40-49, Male, Positive	3
GEND_GBV_DSD	Number of people receiving post-GBV care	2,826
	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	1,540
	By type of service: Sexual Violence (Post-Rape Care)	1,286
	<10, Female, Physical and/or Emotional Violence	92



	<10, Female, Sexual Violence (Post-Rape Care)	77
	<10, Male, Physical and/or Emotional Violence	64
	<10, Male, Sexual Violence (Post-Rape Care)	54
	10-14, Female, Physical and/or Emotional Violence	44
	10-14, Female, Sexual Violence (Post-Rape Care)	36
	10-14, Male, Physical and/or Emotional Violence	29
	10-14, Male, Sexual Violence (Post-Rape Care)	25
	15-19, Female, Physical and/or Emotional Violence	196
	15-19, Female, Sexual Violence (Post-Rape Care)	163
	15-19, Male, Physical and/or Emotional Violence	39
	15-19, Male, Sexual Violence (Post-Rape Care)	33
	20-24, Female, Physical and/or Emotional Violence	290
	20-24, Female, Sexual Violence (Post-Rape Care)	242
	20-24, Male, Physical and/or Emotional Violence	62
	20-24, Male, Sexual Violence (Post-Rape Care)	52
	50+, Female, Physical and/or Emotional Violence	11
	50+, Female, Sexual Violence (Post-Rape Care)	9



	50+, Male, Physical and/or Emotional Violence	32
	50+, Male, Sexual Violence (Post-Rape Care)	26
	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Female, Physical and/or Emotional Violence	276
	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Female, Sexual Violence (Post-Rape Care)	230
	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Male, Physical and/or Emotional Violence	61
	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Male, Sexual Violence (Post-Rape Care)	51
	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Female, Physical and/or Emotional Violence	153
	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Female, Sexual Violence (Post-Rape Care)	127
	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Male, Physical and/or Emotional Violence	50
	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Male, Sexual Violence (Post-Rape Care)	42
	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Female, Physical and/or Emotional Violence	58
	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Female, Sexual Violence (Post-Rape Care)	48
	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Male, Physical and/or Emotional Violence	40



	olenceType_v3 35-39, Male, Physical and/or Emotional Violence	
	GEND_GBV_N_DSD_Age_Sex_Vi olenceType_v3 35-39, Male, Sexual Violence (Post-Rape Care)	34
	GEND_GBV_N_DSD_Age_Sex_Vi olenceType_v3 40-49, Female, Physical and/or Emotional Violence	14
	GEND_GBV_N_DSD_Age_Sex_Vi olenceType_v3 40-49, Female, Sexual Violence (Post-Rape Care)	12
	GEND_GBV_N_DSD_Age_Sex_Vi olenceType_v3 40-49, Male, Physical and/or Emotional Violence	29
	GEND_GBV_N_DSD_Age_Sex_Vi olenceType_v3 40-49, Male, Sexual Violence (Post-Rape Care)	25
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	18,254
	Age/Sex: 10-14 Male	2,715
	Age/Sex: 15-17 Male	1,806
	By: Age/sex: Male 18-24	256
	By: Age/sex: Male 25+	363
	Age/Sex: 10-14 Female	3,667
	Age/Sex: 15-17 Female	2,714
	By: Age/sex: 18-24 Female	782
	By: Age/sex: 25+ Female	3,267
	Sum of Age/Sex disaggregates	10,902
	Age/Sex: <1	384
	Age/Sex: 1-9	2,300
	Program Completion: Active	14,887
	Program Completion: Graduation	1,496



	Program Completion: Transferred	0
	Program Completion: Exited without graduation	1,871
OVC_HIVSTAT_DSD	OVC_HIVSTAT_DSD Number of orphans and vulnerable children (<18 years old) whose HIV status is known or unknown by the OVC implementing partner.	70 %
	Number of orphans and vulnerable children (<18 years old) whose HIV status is known or unknown by the OVC implementing partner.	12,817
	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	18,254
TB_ART_TA	TB_ART_TA Percentage of HIV-positive new and relapsed registered TB cases on ART during TB treatment	n/a
	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	1,519
	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	0
	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB	706





	cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	0
	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	813
TX_TB_TA	TX_TB_TA The proportion of ART patients who were screened who are receiving TB treatment	0 %
	Number of ART patients who were started on TB treatment during the reporting period.	276
	Number of ART patients who were screened for TB at least once during the reporting period	194,573
	Numerator: By Aggregated Age/Sex: <15, Female	0
	Numerator: By Aggregated Age/Sex: <15, Male	0
	Numerator: By Aggregated Age/Sex: 15+, Female	158
	Numerator: By Aggregated Age/Sex: 15+, Male	115



	Denominator: By Aggregated Age/Sex: <15, Female	986
	Denominator: By Aggregated Age/Sex: <15, Male	1,053
	Denominator: By Aggregated Age/Sex: 15+, Female	114,381
	Denominator: By Aggregated Age/Sex: 15+, Male	78,151
	Denominator: By Specimen Sent: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	1,944
	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Other (No Xpert)	1,569
	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	0
	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	375
	TX_TB_D_TA_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Negative, Positive	6
	TX_TB_D_TA_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Positive, Positive	1
	TX_TB_D_TA_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Negative, Positive	0
	TX_TB_D_TA_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Positive, Positive	0



PMTCT_EID_DSD	PMTCT_EID_DSD Percent of infants born to HIV-positive women that receive a virological HIV test within 12 months of birth (DSD)	n/a
	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	7
	By infants who received a virologic test within 2 months of birth	7
	Sum of Infant Age disaggregates	7
PMTCT_EID_TA	PMTCT_EID_TA Percent of infants born to HIV-positive women that receive a virological HIV test within 12 months of birth (TA)	n/a
	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	4,168
	By infants who received a virologic test within 2 months of birth	3,240
	By infants who received their first virologic HIV test between 2 and 12 months of age	928
	Sum of Infant Age disaggregates	4,168
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	1,201
	Age/Sex: 15-19 Male	24
	Age/Sex: 15-19 Female	34
	Age/Sex: 10-14 Male	13
	Age/Sex: 10-14 Female	10
	Age/Sex: 20-24 Male	51
	Age/Sex: 50+ Male	36
	Age/Sex: 20-24 Female	105
	Age/Sex: 50+ Female	59



	TX_CURR_N_DSD_Age_Sex_HIV Status 25-29, Female, Positive	72
	TX_CURR_N_DSD_Age_Sex_HIV Status 25-29, Male, Positive	37
	TX_CURR_N_DSD_Age_Sex_HIV Status 30-34, Female, Positive	116
	TX_CURR_N_DSD_Age_Sex_HIV Status 30-34, Male, Positive	63
	TX_CURR_N_DSD_Age_Sex_HIV Status 35-39, Female, Positive	166
	TX_CURR_N_DSD_Age_Sex_HIV Status 35-39, Male, Positive	87
	TX_CURR_N_DSD_Age_Sex_HIV Status 40-49, Female, Positive	212
	TX_CURR_N_DSD_Age_Sex_HIV Status 40-49, Male, Positive	116
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	197,615
	Age/Sex: 15-19 Male	2,222
	Age/Sex: 15-19 Female	3,783
	Sum of Age/Sex disaggregations	6,005
	Age/Sex: <1	206
	Age/Sex: 1-9	2,638
	Age/Sex: 10-14 Male	1,052
	Age/Sex: 10-14 Female	986
	Age/Sex: 20-24 Male	3,524
	Age/Sex: 50+ Male	19,940
	Age/Sex: 20-24 Female	7,870
	Age/Sex: 50+ Female	23,325
	TX_CURR_N_TA_Age_Sex_HIVSt atus 25-29, Female, Positive	12,250
	TX_CURR_N_TA_Age_Sex_HIVSt	6,139



	atus 25-29, Male, Positive	
	TX_CURR_N_TA_Age_Sex_HIVSt atus 30-34, Female, Positive	17,332
	TX_CURR_N_TA_Age_Sex_HIVSt atus 30-34, Male, Positive	9,881
	TX_CURR_N_TA_Age_Sex_HIVSt atus 35-39, Female, Positive	20,378
	TX_CURR_N_TA_Age_Sex_HIVSt atus 35-39, Male, Positive	13,002
	TX_CURR_N_TA_Age_Sex_HIVSt atus 40-49, Female, Positive	29,575
	TX_CURR_N_TA_Age_Sex_HIVSt atus 40-49, Male, Positive	23,508
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	3,615
	By Age/Sex: 1-9	1
	By Age/Sex: 15-19 Male	37
	By Age/Sex: 20-24 Male	93
	By Age/Sex: 50+ Male	66
	By Age/Sex: 15-19 Female	72
	By Age/Sex: 20-24 Female	141
	By Age/Sex: 50+ Female	69
	FSW	366
	MSM	234
	TX_NEW_N_DSD_Age_Sex_HIVS tatus 25-29, Female, Positive	446
	TX_NEW_N_DSD_Age_Sex_HIVS tatus 25-29, Male, Positive	400
	TX_NEW_N_DSD_Age_Sex_HIVS tatus 30-34, Female, Positive	363
	TX_NEW_N_DSD_Age_Sex_HIVS tatus 30-34, Male, Positive	381



	TX_NEW_N_DSD_Age_Sex_HIVS tatus 35-39, Female, Positive	381
	TX_NEW_N_DSD_Age_Sex_HIVS tatus 35-39, Male, Positive	381
	TX_NEW_N_DSD_Age_Sex_HIVS tatus 40-49, Female, Positive	395
	TX_NEW_N_DSD_Age_Sex_HIVS tatus 40-49, Male, Positive	389
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	35,553
	By Age/Sex: <1	205
	By Age/Sex: 1-9	368
	By Age/Sex: 10-14 Male	0
	By Age/Sex: 15-19 Male	0
	By Age/Sex: 20-24 Male	1,004
	By Age/Sex: 50+ Male	5,331
	By Age/Sex: 10-14 Female	0
	By Age/Sex: 15-19 Female	413
	By Age/Sex: 20-24 Female	1,300
	By Age/Sex: 50+ Female	5,671
	Sum of Age/Sex disaggregates	13,719
	FSW	90
	MSM	63
	TX_NEW_N_TA_Age_Sex_HIVSta tus 25-29, Female, Positive	1,522
	TX_NEW_N_TA_Age_Sex_HIVSta tus 25-29, Male, Positive	1,229
TX_NEW_N_TA_Age_Sex_HIVSta tus 30-34, Female, Positive	1,558	
TX_NEW_N_TA_Age_Sex_HIVSta tus 30-34, Male, Positive	983	
TX_NEW_N_TA_Age_Sex_HIVSta	2,746	



	tus 35-39, Female, Positive	
	TX_NEW_N_TA_Age_Sex_HIVSta tus 35-39, Male, Positive	1,596
	TX_NEW_N_TA_Age_Sex_HIVSta tus 40-49, Female, Positive	6,624
	TX_NEW_N_TA_Age_Sex_HIVSta tus 40-49, Male, Positive	5,003
TX_PVLS_DSD	TX_PVLS_DSD Percentage of ART patients with a viral load result documented in the medical record and/or laboratory information systems (LIS) within the past 12 months with a suppressed viral load (<1000 copies/ml)	0 %
	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	13
	Denominator: Indication: Routine	13
	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	1
	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	12
TX_PVLS_TA	TX_PVLS_TA Percentage of ART patients with a viral load result documented in the medical record and/or laboratory information systems (LIS) within the past 12 months with a suppressed viral load (<1000 copies/ml)	0 %
	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records	159,480



	in the past 12 months.	
	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	1,224
	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	52
	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	1,098
	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	52
	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	99,697
	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	2,964
	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	52,701
	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	1,757
TX_RET_DSD	TX_RET_DSD Percent of adults and children known to be alive and on treatment 12 months after initiation of antiretroviral therapy	83 %
	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	550
	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	666
	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after	2





	initiating ART)	
	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	235
	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	3
	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	310
	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2
	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	328
	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the	3



	beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	333
TX_RET_TA	TX_RET_TA Percent of adults and children known to be alive and on treatment 12 months after initiation of antiretroviral therapy	95 %
	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	35,363
	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	37,120
	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	253
	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	14,240



	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	365
	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	20,508
	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	270
	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	14,912
	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	383
	Aggregated Age/Sex: 15+ Female (Denominator: Total number of	21,573

Approved



	adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
--	--	--



## Partners and Implementing Mechanisms

### Partner List

Mech ID	Partner Name	Organization Type	Agency	Funding Source	Planned Funding
7320	Regional Procurement Support Office/Frankfurt	Other USG Agency	U.S. Department of State/Bureau of African Affairs		
9915	American Society for Microbiology	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention		
14707	U.S. Department of State	Other USG Agency	U.S. Department of State/Bureau of African Affairs	GHP-State	75,000
14790	U.S. Department of State	Other USG Agency	U.S. Department of State/Bureau of African Affairs	GHP-State	93,661
17005	U.S. Peace Corps	Other USG Agency	U.S. Peace Corps	GHP-State	289,211
17007	African Society for Laboratory Medicine	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention		
17274	University of Maryland	University	U.S. Department of Health and	GHP-State	8,666,897



			Human Services/Centers for Disease Control and Prevention		
17275	African Comprehensive HIV/AIDS Partnerships	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	2,909,900
17322	University of North Carolina at Chapel Hill, Carolina Population Center	University	U.S. Agency for International Development	GHP-State	150,000
17323	KNCV Tuberculosis Foundation	NGO	U.S. Agency for International Development	GHP-State	1,070,000
17544	JHPIEGO	University	U.S. Department of Defense		
17845	Botswana Harvard AIDS Institute	Private Contractor	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	400,000
17846	JHPIEGO	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention		



17847	University of Pennsylvania	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	1,500,000
17861	Project Concern International	NGO	U.S. Agency for International Development	GHP-State	5,262,420
17862	FHI 360	NGO	U.S. Agency for International Development	GHP-State	1,373,386
17863	John Snow, Inc.	Private Contractor	U.S. Agency for International Development	GHP-State	3,000,000
18163	University of Washington	University	U.S. Department of Health and Human Services/Health Resources and Services Administration	GHP-State	6,219,204
18220	Global Health Supply Chain Program	Private Contractor	U.S. Agency for International Development	GHP-State	979,808
18252	Government of Botswana	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	2,162,504
18253	University of Maryland	University	U.S. Department of Health and Human	GHP-State	3,507,926



			Services/Centers for Disease Control and Prevention		
18458	Government of Botswana	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention		
18685	Chemonics International	Private Contractor	U.S. Agency for International Development	GHP-State	850,000
70000	TBD	TBD	Redacted	Redacted	Redacted
70001	TBD	TBD	Redacted	Redacted	Redacted
70003	WHO/AFRO	Multi-lateral Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	135,000
70004	Association of Public Health Laboratories	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention		
70013	TBD	TBD	Redacted	Redacted	Redacted
70014	TBD	TBD	Redacted	Redacted	Redacted
70015	TBD	TBD	Redacted	Redacted	Redacted
70016	TBD	TBD	Redacted	Redacted	Redacted
70017	TBD	TBD	Redacted	Redacted	Redacted



Approved





## Implementing Mechanism(s)

### Implementing Mechanism Details

<b>Mechanism ID: 7320</b>	<b>Mechanism Name: RPSO laboratory construction projects</b>
Funding Agency: State/AF	Procurement Type: USG Core
Prime Partner Name: Regional Procurement Support Office/Frankfurt	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
<b>Total All Funding Sources: 0</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b>	7320	
<b>Mechanism Name:</b>	RPSO laboratory construction projects	
<b>Prime Partner Name:</b>	Regional Procurement Support Office/Frankfurt	
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	OHSS	0

### Implementing Mechanism Indicator Information



(No data provided.)

**Implementing Mechanism Details**

<b>Mechanism ID: 9915</b>	<b>Mechanism Name: Capacity building assistance for global HIV/AIDS microbiological labs</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: American Society for Microbiology	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
<b>Total All Funding Sources: 0</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b>	9915	
<b>Mechanism Name:</b>	Capacity building assistance for global HIV/AIDS microbiological labs	
<b>Prime Partner Name:</b>	American Society for Microbiology	
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HBHC	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>



Care	HKID	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HVTB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	PDCS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HLAB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HVSI	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	OHSS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	CIRC	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HMBL	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HMIN	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVAB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVCT	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVOP	0



Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 14707</b>	<b>Mechanism Name: Ambassador's PEPFAR Small Grants Program</b>
Funding Agency: State/AF	Procurement Type: USG Core
Prime Partner Name: U.S. Department of State	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 75,000</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 75,000</b>	
Funding Source	Funding Amount

Approved



GHP-State	75,000
-----------	--------

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b> 14707		
<b>Mechanism Name:</b> Ambassador's PEPFAR Small Grants Program		
<b>Prime Partner Name:</b> U.S. Department of State		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HKID	37,500
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVOP	37,500

**Implementing Mechanism Indicator Information**

(No data provided.)

**Implementing Mechanism Details**

<b>Mechanism ID:</b> 14790	<b>Mechanism Name:</b> Public Affairs/Public Diplomacy (PA/PD) Outreach
Funding Agency: State/AF	Procurement Type: USG Core
Prime Partner Name: U.S. Department of State	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Approved



<b>Total All Funding Sources: 93,661</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 16,399</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 110,060</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	93,661

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b>	14790	
<b>Mechanism Name:</b>	Public Affairs/Public Diplomacy (PA/PD) Outreach	
<b>Prime Partner Name:</b>	U.S. Department of State	
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVOP	93,661

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 17005</b>	<b>Mechanism Name: Peace Corps HIV/AIDS Activities</b>
Funding Agency: PC	Procurement Type: Grant
Prime Partner Name: U.S. Peace Corps	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:



<b>Total All Funding Sources: 289,211</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 289,211</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	289,211

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b>	17005	
<b>Mechanism Name:</b>	Peace Corps HIV/AIDS Activities	
<b>Prime Partner Name:</b>	U.S. Peace Corps	
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HBHC	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HKID	76,270
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HVTB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	PDCS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HLAB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>





Governance and Systems	HVSI	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	OHSS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	CIRC	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HMBL	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HMIN	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVAB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVCT	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVOP	212,941
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	IDUP	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	MTCT	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	HTXD	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	HTXS	0



Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2019
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	10,500
PP_PREV_DSD	Age/sex: 10-14 Male	1,840
PP_PREV_DSD	Age/sex: 15-19 Male	1,895
PP_PREV_DSD	Age/sex: 20-24 Male	1,130
PP_PREV_DSD	Age/sex: 50+ Male	0
PP_PREV_DSD	Age/sex: 10-14 Female	1,900
PP_PREV_DSD	Age/sex: 15-19 Female	1,925
PP_PREV_DSD	Age/sex: 20-24 Female	995
PP_PREV_DSD	Age/sex: 50+ Female	0
PP_PREV_DSD	Sum of Age/Sex disaggregates	9,685
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 25-29, Female	247
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 25-29, Male	158
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 30-34, Female	154
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 30-34, Male	111
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 35-39, Female	64
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 35-39, Male	76
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 40-49, Female	0
PP_PREV_DSD	PP_PREV_N_DSD_Age_Sex_v2 40-49, Male	5
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	899
OVC_SERV_DSD	Age/Sex: 10-14 Male	152
OVC_SERV_DSD	Age/Sex: 15-17 Male	139



OVC_SERV_DSD	By: Age/sex: Male 18-24	74
OVC_SERV_DSD	By: Age/sex: Male 25+	0
OVC_SERV_DSD	Age/Sex: 10-14 Female	207
OVC_SERV_DSD	Age/Sex: 15-17 Female	151
OVC_SERV_DSD	By: Age/sex: 18-24 Female	56
OVC_SERV_DSD	By: Age/sex: 25+ Female	0
OVC_SERV_DSD	Sum of Age/Sex disaggregates	649
OVC_SERV_DSD	Age/Sex: <1	0
OVC_SERV_DSD	Age/Sex: 1-9	120
OVC_SERV_DSD	Program Completion: Active	899
OVC_SERV_DSD	Program Completion: Graduation	0
OVC_SERV_DSD	Program Completion: Transferred	0
OVC_SERV_DSD	Program Completion: Exited without graduation	0

**Implementing Mechanism Details**

<b>Mechanism ID: 17007</b>	<b>Mechanism Name: Development of Lab Network &amp; Society</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: African Society for Laboratory Medicine	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>

**Cross-Cutting Budget Attribution(s)**

(No data provided.)



**Budget Code Information**

<b>Mechanism ID:</b> 17007		
<b>Mechanism Name:</b> Development of Lab Network & Society		
<b>Prime Partner Name:</b> African Society for Laboratory Medicine		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HBHC	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HKID	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HVTB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	PDCS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HLAB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HVSI	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	OHSS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	CIRC	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HMBL	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>



Prevention	HMIN	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVAB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVCT	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVOP	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	IDUP	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	MTCT	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	HTXD	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	HTXS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	PDTX	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 17274</b>	<b>Mechanism Name: Capacity Building and Training</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement



Prime Partner Name: University of Maryland	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 8,666,897</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 8,666,897</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	8,666,897

**Cross-Cutting Budget Attribution(s)**

Adolescent Girls and Young Women (AGYW)	400,000
Motor Vehicles: Purchased	80,000

**Budget Code Information**

<b>Mechanism ID:</b>	17274	
<b>Mechanism Name:</b>	Capacity Building and Training	
<b>Prime Partner Name:</b>	University of Maryland	
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HBHC	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HKID	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HVTB	300,000



Strategic Area	Budget Code	Planned Amount
Care	PDCS	54,000
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	500,000
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount



Prevention	MTCT	450,000
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	HTXD	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	HTXS	6,638,897
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	PDTX	724,000

### Implementing Mechanism Indicator Information

Indicator Number	Label	2019
PMTCT_ART_TA	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	4,100
PMTCT_ART_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	18,536
PMTCT_ART_TA	New on ART	1,145
PMTCT_ART_TA	Already on ART at beginning of current pregnancy	2,955
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	18,536
PMTCT_STAT_TA	Number of new ANC and L&D clients	19,496
PMTCT_STAT_TA	By Age (Denominator): 10-14	4
PMTCT_STAT_TA	By Age (Denominator): 15-19	1,922
PMTCT_STAT_TA	By Age (Denominator): 20-24	5,425
PMTCT_STAT_TA	By Age (Denominator): 50+	0
PMTCT_STAT_TA	By known positives: <10	0
PMTCT_STAT_TA	By known positives: 10-14	0





PMTCT_STAT_TA	By known positives: 15-19	90
PMTCT_STAT_TA	By known positives: 20-24	408
PMTCT_STAT_TA	By known positives: 50+	0
PMTCT_STAT_TA	By new positives: <10	0
PMTCT_STAT_TA	By new positives: 10-14	0
PMTCT_STAT_TA	By new positives: 15-19	43
PMTCT_STAT_TA	By new positives: 20-24	268
PMTCT_STAT_TA	By new positives: 50+	0
PMTCT_STAT_TA	By new negatives: Unknown Age	0
PMTCT_STAT_TA	By new negatives: <10	0
PMTCT_STAT_TA	By new negatives: 10-14	1
PMTCT_STAT_TA	By new negatives: 15-19	1,706
PMTCT_STAT_TA	By new negatives: 20-24	4,412
PMTCT_STAT_TA	By new negatives: 50+	0
PMTCT_STAT_TA	By Age (Numerator): Unknown Age	0
PMTCT_STAT_TA	By Age (Numerator): <10	0
PMTCT_STAT_TA	By Age (Numerator): 10-14	2
PMTCT_STAT_TA	By Age (Numerator): : 15-19	1,851
PMTCT_STAT_TA	By Age (Numerator): 20-24	5,085
PMTCT_STAT_TA	By Age (Numerator): 50+	0
PMTCT_STAT_TA	PMTCT_STAT_D_TA_Age_Sex 25-29, Female	5,095
PMTCT_STAT_TA	PMTCT_STAT_D_TA_Age_Sex 30-34, Female	3,908
PMTCT_STAT_TA	PMTCT_STAT_D_TA_Age_Sex 35-39, Female	2,402
PMTCT_STAT_TA	PMTCT_STAT_D_TA_Age_Sex 40-49, Female	740
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 25-29, Female, Known at Entry Positive	759
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Negative	3,692
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Positive	316
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 30-34, Female, Known at Entry Positive	977



PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Negative	2,574
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Positive	189
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 35-39, Female, Known at Entry Positive	826
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Negative	1,380
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Positive	140
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 40-49, Female, Known at Entry Positive	330
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Negative	366
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Positive	38
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex 25-29, Female	4,769
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex 30-34, Female	3,732
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex 35-39, Female	2,342
PMTCT_STAT_TA	PMTCT_STAT_N_TA_Age_Sex 40-49, Female	742
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	0
TB_ART_TA	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	0
TB_ART_TA	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	0
TB_ART_TA	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during	0



	TB treatment during the reporting period)	
TB_ART_TA	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	0
PMTCT_EID_TA	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	4,168
PMTCT_EID_TA	By infants who received a virologic test within 2 months of birth	3,240
PMTCT_EID_TA	By infants who received their first virologic HIV test between 2 and 12 months of age	928
PMTCT_EID_TA	Sum of Infant Age disaggregates	4,168
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	197,401
TX_CURR_TA	Age/Sex: 15-19 Male	2,218
TX_CURR_TA	Age/Sex: 15-19 Female	3,779
TX_CURR_TA	Sum of Age/Sex disaggregations	5,997
TX_CURR_TA	Age/Sex: <1	206
TX_CURR_TA	Age/Sex: 1-9	2,638
TX_CURR_TA	Age/Sex: 10-14 Male	1,052
TX_CURR_TA	Age/Sex: 10-14 Female	986
TX_CURR_TA	Age/Sex: 20-24 Male	3,519
TX_CURR_TA	Age/Sex: 50+ Male	19,940
TX_CURR_TA	Age/Sex: 20-24 Female	7,849
TX_CURR_TA	Age/Sex: 50+ Female	23,325
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 25-29, Female, Positive	12,241
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 25-29, Male, Positive	6,134
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 30-34, Female, Positive	17,312
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 30-34, Male, Positive	9,871

TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 35-39, Female, Positive	20,332
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 35-39, Male, Positive	12,980
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 40-49, Female, Positive	29,533
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 40-49, Male, Positive	23,482
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	35,406
TX_NEW_TA	By Age/Sex: <1	205
TX_NEW_TA	By Age/Sex: 1-9	368
TX_NEW_TA	By Age/Sex: 10-14 Male	0
TX_NEW_TA	By Age/Sex: 15-19 Male	0
TX_NEW_TA	By Age/Sex: 20-24 Male	995
TX_NEW_TA	By Age/Sex: 50+ Male	5,331
TX_NEW_TA	By Age/Sex: 10-14 Female	0
TX_NEW_TA	By Age/Sex: 15-19 Female	413
TX_NEW_TA	By Age/Sex: 20-24 Female	1,293
TX_NEW_TA	By Age/Sex: 50+ Female	5,671
TX_NEW_TA	Sum of Age/Sex disaggregates	13,703
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 25-29, Female, Positive	1,506
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 25-29, Male, Positive	1,216
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 30-34, Female, Positive	1,533
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 30-34, Male, Positive	970
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 35-39, Female, Positive	2,737
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 35-39, Male, Positive	1,591

TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 40-49, Female, Positive	6,591
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 40-49, Male, Positive	4,980
TX_PVLS_TA	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	159,480
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	1,224
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	52
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	1,098
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	52
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	99,697
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	2,964
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	52,701
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	1,757
TX_RET_TA	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	35,247
TX_RET_TA	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	36,997
TX_RET_TA	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	253
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment	14,198



	at 12 months after initiating ART)	
TX_RET_TA	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	365
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	20,434
TX_RET_TA	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	270
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	14,908
TX_RET_TA	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	383
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	21,454
TX_TB_TA	Number of ART patients who were started on TB treatment during the reporting period.	264
TX_TB_TA	Number of ART patients who were screened for TB at least once during the reporting period	194,566
TX_TB_TA	Numerator: By Aggregated Age/Sex: <15, Female	0
TX_TB_TA	Numerator: By Aggregated Age/Sex: <15, Male	0
TX_TB_TA	Numerator: By Aggregated Age/Sex: 15+, Female	152
TX_TB_TA	Numerator: By Aggregated Age/Sex: 15+, Male	109



TX_TB_TA	Denominator: By Aggregated Age/Sex: <15, Female	986
TX_TB_TA	Denominator: By Aggregated Age/Sex: <15, Male	1,053
TX_TB_TA	Denominator: By Aggregated Age/Sex: 15+, Female	114,374
TX_TB_TA	Denominator: By Aggregated Age/Sex: 15+, Male	78,151
TX_TB_TA	Denominator: By Specimen Sent: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	1,944
TX_TB_TA	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Other (No Xpert)	1,569
TX_TB_TA	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	0
TX_TB_TA	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	375
TX_TB_TA	TX_TB_D_TA_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Negative, Positive	0
TX_TB_TA	TX_TB_D_TA_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Positive, Positive	0
TX_TB_TA	TX_TB_D_TA_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Negative, Positive	0
TX_TB_TA	TX_TB_D_TA_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Positive, Positive	0

### Implementing Mechanism Details

<b>Mechanism ID: 17275</b>	<b>Mechanism Name: Voluntary Medical Male Circumcision</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: African Comprehensive HIV/AIDS Partnerships	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
<b>Total All Funding Sources: 2,909,900</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 350,000</b>	



<b>Total All Funding Sources and Applied Pipeline Amount: 3,259,900</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	2,909,900

**Cross-Cutting Budget Attribution(s)**

Motor Vehicles: Purchased	80,000
Adolescent Girls and Young Women (AGYW)	100,000

**Budget Code Information**

<b>Mechanism ID: 17275</b>		
<b>Mechanism Name: Voluntary Medical Male Circumcision</b>		
<b>Prime Partner Name: African Comprehensive HIV/AIDS Partnerships</b>		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HBHC	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HKID	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HVTB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	PDCS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HLAB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HVSI	0





Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	2,809,900
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	100,000
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount



Treatment	PDTX	0
-----------	------	---

### Implementing Mechanism Indicator Information

Indicator Number	Label	2019
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	18,370
VMMC_CIRC_DSD	By Age: 10-14	6,430
VMMC_CIRC_DSD	By Age: 15-19	5,512
VMMC_CIRC_DSD	By Age: 20-24	1,836
VMMC_CIRC_DSD	By Age: 25-29	1,837
VMMC_CIRC_DSD	By Age: 50+	367
VMMC_CIRC_DSD	Sum of age disaggregates (Prior to FY15)	14,145
VMMC_CIRC_DSD	Sum of age disaggregates (FY15-Current)	15,982
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	18,323
VMMC_CIRC_DSD	VMMC_CIRC_N_DSD_Age_Sex 30-34, Male	1,286
VMMC_CIRC_DSD	VMMC_CIRC_N_DSD_Age_Sex 35-39, Male	736
VMMC_CIRC_DSD	VMMC_CIRC_N_DSD_Age_Sex 40-49, Male	367

### Implementing Mechanism Details

<b>Mechanism ID: 17322</b>	<b>Mechanism Name: MEASURE Evaluation Phase IV</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: University of North Carolina at Chapel Hill, Carolina Population Center	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
<b>Total All Funding Sources: 150,000</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 344,978</b>	



<b>Total All Funding Sources and Applied Pipeline Amount: 494,978</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	150,000

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b>	17322	
<b>Mechanism Name:</b>	MEASURE Evaluation Phase IV	
<b>Prime Partner Name:</b>	University of North Carolina at Chapel Hill, Carolina Population Center	
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HBHC	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HKID	150,000
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HVTB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	PDCS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HLAB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HVSI	0



Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount



Treatment	PDTX	0
-----------	------	---

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 17323</b>	<b>Mechanism Name: Challenge TB</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: KNCV Tuberculosis Foundation	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 1,070,000</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 1,070,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	1,070,000

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b>	17323	
<b>Mechanism Name:</b>	Challenge TB	
<b>Prime Partner Name:</b>	KNCV Tuberculosis Foundation	
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>



Care	HBHC	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HKID	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HVTB	1,070,000
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	PDCS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HLAB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HVSI	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	OHSS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	CIRC	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HMBL	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HMIN	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVAB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVCT	0



Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 17544</b>	<b>Mechanism Name: BDF Prevention and Circumcision Program</b>
Funding Agency: DOD	Procurement Type: Grant
Prime Partner Name: JHPIEGO	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
<b>Total All Funding Sources: 0</b>	<b>Total Mechanism Pipeline: N/A</b>



<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID: 17544</b>		
<b>Mechanism Name: BDF Prevention and Circumcision Program</b>		
<b>Prime Partner Name: JHPIEGO</b>		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HBHC	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HKID	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HVTB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	PDCS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HLAB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HVSI	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>





Governance and Systems	OHSS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	CIRC	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HMBL	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HMIN	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVAB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVCT	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVOP	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	IDUP	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	MTCT	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	HTXD	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	HTXS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	PDTX	0



## Implementing Mechanism Indicator Information

Indicator Number	Label	2019
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	0
VMMC_CIRC_DSD	By Age: 15-19	0
VMMC_CIRC_DSD	By Age: 20-24	0
VMMC_CIRC_DSD	By Age: 25-29	0
VMMC_CIRC_DSD	By Age: 50+	0
VMMC_CIRC_DSD	Sum of age disaggregates (Prior to FY15)	0
VMMC_CIRC_DSD	Sum of age disaggregates (FY15-Current)	0
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	0
VMMC_CIRC_DSD	VMMC_CIRC_N_DSD_Age_Sex 30-34, Male	0
VMMC_CIRC_DSD	VMMC_CIRC_N_DSD_Age_Sex 35-39, Male	0
VMMC_CIRC_DSD	VMMC_CIRC_N_DSD_Age_Sex 40-49, Male	0
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	0
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 10-14, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 10-14, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 15-19, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 15-19, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 50+, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 50+, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	0



HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Positive	0
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Negative	0
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Positive	0
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Negative	0
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Positive	0
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Negative	0
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Positive	0
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Negative	0
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Positive	0
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 25-29, Male, Negative	0
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 25-29, Male, Positive	0
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 30-34, Male, Negative	0
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 30-34, Male, Positive	0



HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 35-39, Male, Negative	0
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 35-39, Male, Positive	0
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 40-49, Male, Negative	0
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 40-49, Male, Positive	0
HTS_SELF_DSD	HTS_SELF_N_DSD	0
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Unassisted	0

**Implementing Mechanism Details**

<b>Mechanism ID: 17845</b>	<b>Mechanism Name: Capacity Building through Training and Mentoring for Informatics</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Botswana Harvard AIDS Institute	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 400,000</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 400,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	400,000

**Cross-Cutting Budget Attribution(s)**

Motor Vehicles: Purchased	80,000
---------------------------	--------



**Budget Code Information**

<b>Mechanism ID:</b>	17845	
<b>Mechanism Name:</b>	Capacity Building through Training and Mentoring for Informatics	
<b>Prime Partner Name:</b>	Botswana Harvard AIDS Institute	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount



Prevention	HMIN	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVAB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVCT	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVOP	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	IDUP	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	MTCT	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	HTXD	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	HTXS	400,000
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	PDTX	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 17846</b>	<b>Mechanism Name: Capacity Building through Training and Mentoring for Cervical Cancer</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement



Prime Partner Name: JHPIEGO	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b> 17846 <b>Mechanism Name:</b> Capacity Building through Training and Mentoring for Cervical Cancer <b>Prime Partner Name:</b> JHPIEGO		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HBHC	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HKID	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HVTB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>



Care	PDCS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HLAB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HVSI	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	OHSS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	CIRC	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HMBL	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HMIN	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVAB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVCT	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVOP	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	IDUP	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	MTCT	0





Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 17847</b>	<b>Mechanism Name: Capacity Building through Training and Mentoring for TB/HIV</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: University of Pennsylvania	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 1,500,000</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 1,500,000</b>	
Funding Source	Funding Amount
GHP-State	1,500,000

### Cross-Cutting Budget Attribution(s)

(No data provided.)



**Budget Code Information**

<b>Mechanism ID:</b> 17847		
<b>Mechanism Name:</b> Capacity Building through Training and Mentoring for TB/HIV		
<b>Prime Partner Name:</b> University of Pennsylvania		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HBHC	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HKID	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HVTB	1,500,000
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	PDCS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HLAB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HVSI	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	OHSS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	CIRC	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HMBL	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>



Prevention	HMIN	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVAB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVCT	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVOP	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	IDUP	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	MTCT	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	HTXD	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	HTXS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	PDTX	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2019
TB_STAT_TA	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	2,540
TB_STAT_TA	Total number of registered new and relapsed TB cases,	2,540



	during the reporting period.	
TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	1,132
TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	1,409
TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,409
TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,132
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	1,519
TB_ART_TA	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	706
TB_ART_TA	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	813
TX_TB_TA	Number of ART patients who were started on TB treatment during the reporting period.	12
TX_TB_TA	Numerator: By Aggregated Age/Sex: 15+, Female	6
TX_TB_TA	Numerator: By Aggregated Age/Sex: 15+, Male	6

### Implementing Mechanism Details

<b>Mechanism ID: 17861</b>	<b>Mechanism Name: Botswana Comprehensive Care and Support for Orphans and Vulnerable Children Project (former OVC TBD)</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Project Concern International	



Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 5,262,420</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 5,262,420</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	5,262,420

**Cross-Cutting Budget Attribution(s)**

Gender: GBV	727,250
Focus Area:	GBV Prevention
Sub Area:	Capacity building
Sub Area:	Collection and Use of Gender-related Strategic Information
Gender: Gender Equality	500,000
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Capacity building
Adolescent Girls and Young Women (AGYW)	2,277,250
Water	50,000

**Budget Code Information**

<b>Mechanism ID:</b>	17861
<b>Mechanism Name:</b>	Botswana Comprehensive Care and Support for Orphans and Vulnerable Children Project (former OVC TBD)
<b>Prime Partner Name:</b>	Project Concern International



Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	2,985,170
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	200,000
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	1,429,625
Strategic Area	Budget Code	Planned Amount



Prevention	HVCT	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVOP	647,625
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	IDUP	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	MTCT	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	HTXD	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	HTXS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	PDTX	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2019
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	13,064
PP_PREV_DSD	Age/sex: 10-14 Male	1,000
PP_PREV_DSD	Age/sex: 15-19 Male	84
PP_PREV_DSD	Age/sex: 20-24 Male	261
PP_PREV_DSD	Age/sex: 10-14 Female	2,000
PP_PREV_DSD	Age/sex: 15-19 Female	4,391
PP_PREV_DSD	Age/sex: 20-24 Female	5,328
PP_PREV_DSD	Sum of Age/Sex disaggregates	13,064



OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	17,355
OVC_SERV_DSD	Age/Sex: 10-14 Male	2,563
OVC_SERV_DSD	Age/Sex: 15-17 Male	1,667
OVC_SERV_DSD	By: Age/sex: Male 18-24	182
OVC_SERV_DSD	By: Age/sex: Male 25+	363
OVC_SERV_DSD	Age/Sex: 10-14 Female	3,460
OVC_SERV_DSD	Age/Sex: 15-17 Female	2,563
OVC_SERV_DSD	By: Age/sex: 18-24 Female	726
OVC_SERV_DSD	By: Age/sex: 25+ Female	3,267
OVC_SERV_DSD	Sum of Age/Sex disaggregates	10,253
OVC_SERV_DSD	Age/Sex: <1	384
OVC_SERV_DSD	Age/Sex: 1-9	2,180
OVC_SERV_DSD	Program Completion: Active	13,988
OVC_SERV_DSD	Program Completion: Graduation	1,496
OVC_SERV_DSD	Program Completion: Exited without graduation	1,871
OVC_HIVSTAT_DSD	Number of orphans and vulnerable children (<18 years old) whose HIV status is known or unknown by the OVC implementing partner.	12,817
OVC_HIVSTAT_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	17,355

**Implementing Mechanism Details**

<b>Mechanism ID: 17862</b>	<b>Mechanism Name: Linkages Across the Continuum of HIV Services for Key Populations Affected by HIV (LINKAGES) Project</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: FHI 360	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	





G2G: No	Managing Agency:
<b>Total All Funding Sources: 1,373,386</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 1,373,386</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	1,373,386

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b>	17862	
<b>Mechanism Name:</b>	Linkages Across the Continuum of HIV Services for Key	
<b>Prime Partner Name:</b>	Populations Affected by HIV (LINKAGES) Project	
	FHI 360	
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HBHC	256,332
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HKID	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HVTB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	PDCS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HLAB	0



Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	91,454
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	424,773
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount



Treatment	HTXS	600,827
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	PDTX	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2019
PrEP_NEW_DSD	Number of individuals who have been newly enrolled on oral antiretroviral pre-exposure prophylaxis (PrEP) in the reporting period to prevent HIV infection	141
PrEP_NEW_DSD	Male 15-19	17
PrEP_NEW_DSD	Male 20-24	16
PrEP_NEW_DSD	Male 50+	3
PrEP_NEW_DSD	Female 15-19	17
PrEP_NEW_DSD	Female 20-24	16
PrEP_NEW_DSD	Female 50+	2
PrEP_NEW_DSD	FSW	70
PrEP_NEW_DSD	MSM	71
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Female	16
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Male	16
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Female	7
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Male	7
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Female	7
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Male	7
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 40-49, Female	5
PrEP_NEW_DSD	PrEP_NEW_N_DSD_Age_Sex_v2 40-49, Male	5
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	3,858
KP_PREV_DSD	By key population type: Men who have sex with men	150



	who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	1,349
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	2,359
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	2,773
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Negative	172
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Positive	29
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Negative	254
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Positive	44
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Negative	172
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Positive	29
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Negative	221
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Positive	38
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Female, Negative	87



HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Female, Positive	16
HTC_TST_DSD	Service Delivery Point (Community) Other: 15-19, Female, Negative	11
HTC_TST_DSD	Service Delivery Point (Community) Other: 15-19, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Community) Other: 15-19, Male, Negative	9
HTC_TST_DSD	Service Delivery Point (Community) Other: 15-19, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Community) Other: 20-24, Female, Negative	15
HTC_TST_DSD	Service Delivery Point (Community) Other: 20-24, Female, Positive	2
HTC_TST_DSD	Service Delivery Point (Community) Other: 20-24, Male, Negative	14
HTC_TST_DSD	Service Delivery Point (Community) Other: 20-24, Male, Positive	3
HTC_TST_DSD	Service Delivery Point (Community) Other: 50+, Female, Negative	32
HTC_TST_DSD	Service Delivery Point (Community) Other: 50+, Female, Positive	5
HTC_TST_DSD	Service Delivery Point (Community) Other: 50+, Male, Negative	32
HTC_TST_DSD	Service Delivery Point (Community) Other: 50+, Male, Positive	3
HTC_TST_DSD	By Key Population: FSW, Negative	1,191
HTC_TST_DSD	By Key Population: FSW, Positive	208
HTC_TST_DSD	By Key Population: MSM, Negative	745
HTC_TST_DSD	By Key Population: MSM, Positive	132
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 15-19, Female, Negative	8
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 15-19, Female, Positive	1



HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 15-19, Male, Negative	7
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 15-19, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 20-24, Female, Negative	9
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 20-24, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 20-24, Male, Negative	10
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 20-24, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 50+, Female, Negative	8
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 50+, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Female, Negative	172
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Female, Positive	31
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Male, Negative	173
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Male, Positive	31
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Female, Negative	87
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Female, Positive	16
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Male, Negative	88
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Male, Positive	16
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Female, Negative	87



HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Female, Positive	16
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Male, Negative	87
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Male, Positive	16
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Female, Negative	87
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Female, Positive	16
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Male, Negative	35
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Male, Positive	6
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 25-29, Female, Negative	15
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 25-29, Female, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 25-29, Male, Negative	16
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 25-29, Male, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 30-34, Female, Negative	23
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 30-34, Female, Positive	6
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 30-34, Male, Negative	24
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 30-34, Male, Positive	6
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Female, Negative	70
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Female, Positive	13

HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Male, Negative	70
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Male, Positive	13
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Female, Negative	69
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Female, Positive	12
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Male, Negative	71
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Male, Positive	11
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 25-29, Female, Negative	25
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 25-29, Female, Positive	6
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 25-29, Male, Negative	14
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 25-29, Male, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 30-34, Female, Negative	24
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 30-34, Female, Positive	6
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 30-34, Male, Negative	23
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 30-34, Male, Positive	5
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 35-39, Female, Negative	10
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 35-39, Female, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 35-39, Male, Negative	10





HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 35-39, Male, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 40-49, Female, Negative	9
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 40-49, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 40-49, Male, Negative	8
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 40-49, Male, Positive	1
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	428
TX_CURR_DSD	Age/Sex: 15-19 Male	11
TX_CURR_DSD	Age/Sex: 15-19 Female	15
TX_CURR_DSD	Sum of age/sex disaggregates	26
TX_CURR_DSD	Age/Sex: 20-24 Male	25
TX_CURR_DSD	Age/Sex: 50+ Male	4
TX_CURR_DSD	Age/Sex: 20-24 Female	51
TX_CURR_DSD	Age/Sex: 50+ Female	9
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	25
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	14
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	43
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	24
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	65
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	34
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	79
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Male,	29



	Positive	
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	214
TX_CURR_TA	Age/Sex: 15-19 Male	4
TX_CURR_TA	Age/Sex: 15-19 Female	4
TX_CURR_TA	Sum of Age/Sex disaggregations	8
TX_CURR_TA	Age/Sex: 20-24 Male	5
TX_CURR_TA	Age/Sex: 20-24 Female	21
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 25-29, Female, Positive	9
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 25-29, Male, Positive	5
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 30-34, Female, Positive	20
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 30-34, Male, Positive	10
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 35-39, Female, Positive	46
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 35-39, Male, Positive	22
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 40-49, Female, Positive	42
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 40-49, Male, Positive	26
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	300
TX_NEW_DSD	By Age/Sex: 15-19 Male	4
TX_NEW_DSD	By Age/Sex: 20-24 Male	16
TX_NEW_DSD	By Age/Sex: 50+ Male	3
TX_NEW_DSD	By Age/Sex: 15-19 Female	6
TX_NEW_DSD	By Age/Sex: 20-24 Female	25
TX_NEW_DSD	By Age/Sex: 50+ Female	4
TX_NEW_DSD	Sum of Age/Sex disaggregates	58



TX_NEW_DSD	FSW	183
TX_NEW_DSD	MSM	117
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	26
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	19
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	32
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	22
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	41
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	25
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	48
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	29
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	147
TX_NEW_TA	By Age/Sex: 20-24 Male	9
TX_NEW_TA	By Age/Sex: 20-24 Female	7
TX_NEW_TA	Sum of Age/Sex disaggregates	16
TX_NEW_TA	FSW	90
TX_NEW_TA	MSM	63
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 25-29, Female, Positive	16
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 25-29, Male, Positive	13
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 30-34, Female, Positive	25
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 30-34, Male, Positive	13
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 35-39, Female,	9



	Positive	
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 35-39, Male, Positive	5
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 40-49, Female, Positive	33
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 40-49, Male, Positive	23
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	254
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	311
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	104
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	150
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	150
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	161
TX_RET_TA	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	116
TX_RET_TA	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	123



TX_RET_TA	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	42
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	74
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	4
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	119
HTS_SELF_DSD	HTS_SELF_N_DSD	1,433
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Unassisted	28
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Unassisted	28
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Unassisted	42
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Unassisted	43
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Unassisted	44
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Unassisted	44
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Unassisted	73
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Unassisted	72
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Unassisted	215



HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Unassisted	215
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Unassisted	215
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Unassisted	214
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Unassisted	100
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Unassisted	100
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Unassisted	1,433
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Self	287
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Sex Partner	975
TX_TB_TA	Number of ART patients who were screened for TB at least once during the reporting period	7
TX_TB_TA	Denominator: By Aggregated Age/Sex: 15+, Female	7
TX_TB_TA	TX_TB_D_TA_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Negative, Positive	6
TX_TB_TA	TX_TB_D_TA_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Positive, Positive	1

### Implementing Mechanism Details

<b>Mechanism ID: 17863</b>	<b>Mechanism Name: Advancing Partners and Communities Project</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: John Snow, Inc.	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
<b>Total All Funding Sources: 3,000,000</b>	<b>Total Mechanism Pipeline: N/A</b>



<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 3,000,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	3,000,000

**Cross-Cutting Budget Attribution(s)**

Gender: GBV	100,000
Focus Area:	GBV Prevention
Sub Area:	Capacity building
Adolescent Girls and Young Women (AGYW)	434,430

**Budget Code Information**

<b>Mechanism ID: 17863</b>		
<b>Mechanism Name: Advancing Partners and Communities Project</b>		
<b>Prime Partner Name: John Snow, Inc.</b>		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HBHC	954,809
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HKID	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HVTB	187,021
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	PDCS	73,473
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HLAB	0



Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	842,667
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	289,903
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	211,432
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount





Treatment	HTXS	440,695
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	PDTX	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2019
PrEP_NEW_DSD	Number of individuals who have been newly enrolled on oral antiretroviral pre-exposure prophylaxis (PrEP) in the reporting period to prevent HIV infection	179
PrEP_NEW_DSD	Female 15-19	60
PrEP_NEW_DSD	Female 20-24	119
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	48,508
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 10-14, Female, Negative	9
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Negative	788
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Positive	6
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Negative	170
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Positive	14
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Negative	785
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Positive	10
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Negative	196
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing:	31



	20-24, Male, Positive	
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Female, Negative	236
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Female, Positive	16
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Negative	236
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Positive	9
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: <1, Negative	15
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: <1, Positive	1
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 1-9, Negative	4
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	107
HTC_TST_DSD	Service Delivery Point (Community) Other: 10-14, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Community) Other: 10-14, Male, Negative	105
HTC_TST_DSD	Service Delivery Point (Community) Other: 15-19, Female, Negative	2,789
HTC_TST_DSD	Service Delivery Point (Community) Other: 15-19, Female, Positive	15
HTC_TST_DSD	Service Delivery Point (Community) Other: 15-19, Male, Negative	568
HTC_TST_DSD	Service Delivery Point (Community) Other: 15-19, Male, Positive	29
HTC_TST_DSD	Service Delivery Point (Community) Other: 20-24, Female, Negative	2,789
HTC_TST_DSD	Service Delivery Point (Community) Other: 20-24, Female, Positive	15
HTC_TST_DSD	Service Delivery Point (Community) Other: 20-24, Male,	568



	Negative	
HTC_TST_DSD	Service Delivery Point (Community) Other: 20-24, Male, Positive	29
HTC_TST_DSD	Service Delivery Point (Community) Other: 50+, Female, Negative	859
HTC_TST_DSD	Service Delivery Point (Community) Other: 50+, Female, Positive	57
HTC_TST_DSD	Service Delivery Point (Community) Other: 50+, Male, Negative	859
HTC_TST_DSD	Service Delivery Point (Community) Other: 50+, Male, Positive	71
HTC_TST_DSD	Service Delivery Point (Community) Other: <1, Negative	4
HTC_TST_DSD	Service Delivery Point (Community) Other: <1, Positive	5
HTC_TST_DSD	Service Delivery Point (Community) Other: 1-9, Negative	8
HTC_TST_DSD	Service Delivery Point (Community) Other: 1-9, Positive	6
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Female, Negative	26
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Male, Negative	17
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Negative	369
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Positive	11
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Negative	145
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Positive	9
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Negative	382
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Positive	35
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Negative	147



HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Positive	36
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Female, Negative	173
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Female, Positive	59
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Negative	173
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Positive	59
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: <1, Negative	67
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: <1, Positive	8
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 1-9, Negative	70
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 1-9, Positive	1
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 10-14, Female, Negative	2
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 10-14, Male, Negative	2
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 15-19, Female, Negative	366
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 15-19, Female, Positive	4
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 15-19, Male, Negative	76
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 15-19, Male, Positive	2
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 20-24, Female, Negative	410
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 20-24, Female, Positive	2



HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 20-24, Male, Negative	88
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 20-24, Male, Positive	5
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 50+, Female, Negative	72
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 50+, Female, Positive	6
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 50+, Male, Negative	45
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 50+, Male, Positive	8
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: <1, Negative	11
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: <1, Positive	1
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 1-9, Negative	11
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Female, Negative	758
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Female, Positive	46
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Male, Negative	842
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Male, Positive	45
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Female, Negative	902
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Female, Positive	57
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Male, Negative	996
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Male, Positive	41



HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Female, Negative	615
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Female, Positive	53
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Male, Negative	708
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Male, Positive	45
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Female, Negative	504
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Female, Positive	54
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Male, Negative	588
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Male, Positive	19
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Negative	203
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Positive	81
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Negative	209
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Positive	92
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Negative	241
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Positive	81
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Negative	246
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Positive	99
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Female, Negative	440

HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Female, Positive	107
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Negative	484
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Positive	84
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Female, Negative	287
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Female, Positive	72
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Negative	257
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Positive	75
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 25-29, Female, Negative	2,604
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 25-29, Female, Positive	131
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 25-29, Male, Negative	2,933
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 25-29, Male, Positive	162
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 30-34, Female, Negative	3,172
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 30-34, Female, Positive	146
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 30-34, Male, Negative	3,503
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 30-34, Male, Positive	176
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Female, Negative	2,087
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Female, Positive	161



HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Male, Negative	2,392
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Male, Positive	162
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Female, Negative	1,823
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Female, Positive	134
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Male, Negative	2,127
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Male, Positive	177
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 25-29, Female, Negative	447
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 25-29, Female, Positive	16
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 25-29, Male, Negative	478
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 25-29, Male, Positive	17
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 30-34, Female, Negative	431
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 30-34, Female, Positive	19
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 30-34, Male, Negative	403
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 30-34, Male, Positive	22
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 35-39, Female, Negative	309
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 35-39, Female, Positive	17
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 35-39, Male, Negative	342





HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 35-39, Male, Positive	20
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 40-49, Female, Negative	201
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 40-49, Female, Positive	21
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 40-49, Male, Negative	220
HTC_TST_DSD	HTS_TST_N_DSD_VCTMod_Age_Sex_Result 40-49, Male, Positive	16
GEND_GBV_DSD	Number of people receiving post-GBV care	848
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	551
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	297
GEND_GBV_DSD	<10, Female, Physical and/or Emotional Violence	32
GEND_GBV_DSD	<10, Female, Sexual Violence (Post-Rape Care)	17
GEND_GBV_DSD	<10, Male, Physical and/or Emotional Violence	23
GEND_GBV_DSD	<10, Male, Sexual Violence (Post-Rape Care)	13
GEND_GBV_DSD	10-14, Female, Physical and/or Emotional Violence	16
GEND_GBV_DSD	10-14, Female, Sexual Violence (Post-Rape Care)	8
GEND_GBV_DSD	10-14, Male, Physical and/or Emotional Violence	10
GEND_GBV_DSD	10-14, Male, Sexual Violence (Post-Rape Care)	6
GEND_GBV_DSD	15-19, Female, Physical and/or Emotional Violence	70
GEND_GBV_DSD	15-19, Female, Sexual Violence (Post-Rape Care)	37
GEND_GBV_DSD	15-19, Male, Physical and/or Emotional Violence	14
GEND_GBV_DSD	15-19, Male, Sexual Violence (Post-Rape Care)	8
GEND_GBV_DSD	20-24, Female, Physical and/or Emotional Violence	104
GEND_GBV_DSD	20-24, Female, Sexual Violence (Post-Rape Care)	56
GEND_GBV_DSD	20-24, Male, Physical and/or Emotional Violence	22
GEND_GBV_DSD	20-24, Male, Sexual Violence (Post-Rape Care)	12
GEND_GBV_DSD	50+, Female, Physical and/or Emotional Violence	4
GEND_GBV_DSD	50+, Female, Sexual Violence (Post-Rape Care)	2
GEND_GBV_DSD	50+, Male, Physical and/or Emotional Violence	12



GEND_GBV_DSD	50+, Male, Sexual Violence (Post-Rape Care)	6
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Female, Physical and/or Emotional Violence	99
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Female, Sexual Violence (Post-Rape Care)	53
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Male, Physical and/or Emotional Violence	22
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Male, Sexual Violence (Post-Rape Care)	12
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Female, Physical and/or Emotional Violence	55
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Female, Sexual Violence (Post-Rape Care)	29
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Male, Physical and/or Emotional Violence	18
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Male, Sexual Violence (Post-Rape Care)	10
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Female, Physical and/or Emotional Violence	21
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Female, Sexual Violence (Post-Rape Care)	11
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Male, Physical and/or Emotional Violence	14
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Male, Sexual Violence (Post-Rape Care)	8
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Female, Physical and/or Emotional Violence	5
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Female, Sexual Violence (Post-Rape Care)	3
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Male, Physical and/or Emotional Violence	10
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Male, Sexual Violence (Post-Rape Care)	6
TX_NEW_DSD	Number of adults and children newly enrolled on	900



	antiretroviral therapy (ART)	
TX_NEW_DSD	By Age/Sex: 15-19 Male	9
TX_NEW_DSD	By Age/Sex: 20-24 Male	19
TX_NEW_DSD	By Age/Sex: 50+ Male	17
TX_NEW_DSD	By Age/Sex: 15-19 Female	18
TX_NEW_DSD	By Age/Sex: 20-24 Female	27
TX_NEW_DSD	By Age/Sex: 50+ Female	17
TX_NEW_DSD	Sum of Age/Sex disaggregates	107
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	118
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	108
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	89
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	100
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	89
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	100
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	89
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	100
HTS_SELF_DSD	HTS_SELF_N_DSD	2,578
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Unassisted	51
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Unassisted	51
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Unassisted	76
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Unassisted	77



HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Unassisted	76
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Unassisted	77
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Unassisted	130
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Unassisted	130
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Unassisted	387
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Unassisted	387
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Unassisted	387
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Unassisted	387
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Unassisted	181
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Unassisted	181
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Unassisted	2,578
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Self	515
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Sex Partner	2,063

### Implementing Mechanism Details

<b>Mechanism ID: 18163</b>	<b>Mechanism Name: Technical assistance to strengthen government health systems</b>
Funding Agency: HHS/HRSA	Procurement Type: Cooperative Agreement
Prime Partner Name: University of Washington	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	



G2G: No	Managing Agency:
<b>Total All Funding Sources: 6,219,204</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 6,219,204</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	6,219,204

**Cross-Cutting Budget Attribution(s)**

Motor Vehicles: Purchased	100,000
Adolescent Girls and Young Women (AGYW)	337,229

**Budget Code Information**

<b>Mechanism ID: 18163</b>		
<b>Mechanism Name: Technical assistance to strengthen government health systems</b>		
<b>Prime Partner Name: University of Washington</b>		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HBHC	613,442
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HKID	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HVTB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	PDCS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>



Governance and Systems	HLAB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HVSI	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	OHSS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	CIRC	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HMBL	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HMIN	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVAB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVCT	4,479,451
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVOP	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	IDUP	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	MTCT	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	HTXD	0



Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	826,311
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	300,000

### Implementing Mechanism Indicator Information

Indicator Number	Label	2019
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	284,928
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	265
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	16
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	18
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	609
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	41
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	568
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	44
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	2,949
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Positive	204



HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	2,569
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	173
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Negative	611
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Positive	46
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Negative	276
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Positive	23
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	2,215
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	172
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	6,315
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	484
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	5,149
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	391
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	21,174
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	1,667
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	18,537
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	1,456
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Negative	530
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Positive	20
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Negative	239





HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Positive	6
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Negative	278
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Positive	22
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Negative	7
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Negative	30
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Negative	14
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Negative	127
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Positive	22
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Negative	89
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Positive	7
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 10-14, Negative	6,551
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 10-14, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 15-19, Negative	5,513
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 15-19, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 1-9, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24, Negative	1,933
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 50+, Negative	373
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Negative	420
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Positive	74
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Negative	1,213



HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Positive	216
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Negative	990
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Positive	179
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Negative	3,880
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Positive	757
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Negative	3,387
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Positive	671
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Negative	2,713
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Positive	141
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Negative	1,196
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Positive	64
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Negative	1,401
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Positive	42
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Negative	3,612
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Positive	222
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	425
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Positive	21
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	1,351
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	81
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	940
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Positive	65



HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Negative	5,735
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Positive	333
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Negative	5,020
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Positive	291
HTC_TST_DSD	Service Delivery Point (Facility) VCT: <1, Negative	276
HTC_TST_DSD	Service Delivery Point (Facility) VCT: <1, Positive	8
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Negative	128
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result <1, Unknown Sex, Negative	215
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result <1, Unknown Sex, Positive	12
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 15-19, Female, Negative	34
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 15-19, Female, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 1-9, Unknown Sex, Negative	95
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 1-9, Unknown Sex, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 20-24, Female, Negative	107
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 20-24, Female, Positive	6
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 20-24, Male, Negative	93
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 20-24, Male, Positive	8
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 25-29, Female, Negative	137



HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 25-29, Female, Positive	7
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 25-29, Male, Negative	132
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 25-29, Male, Positive	10
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 30-34, Female, Negative	112
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 30-34, Female, Positive	6
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 30-34, Male, Negative	97
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 30-34, Male, Positive	8
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 35-39, Female, Negative	180
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 35-39, Female, Positive	22
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 35-39, Male, Negative	135
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 35-39, Male, Positive	10
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 40-49, Female, Negative	436
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 40-49, Female, Positive	53
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 40-49, Male, Negative	316
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 40-49, Male, Positive	36
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 50+, Female, Negative	384
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 50+, Female, Positive	45



HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 50+, Male, Negative	334
HTC_TST_DSD	HTS_TST_N_DSD_EW_Age_Sex_Result 50+, Male, Positive	39
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Negative	1,454
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Positive	264
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Negative	1,435
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Positive	249
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Negative	1,130
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Positive	223
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Negative	1,217
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Positive	200
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Negative	1,831
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Positive	357
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Negative	1,557
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Positive	270
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Negative	4,438
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Positive	867
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Negative	3,211



HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Positive	633
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Negative	845
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Positive	55
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Negative	731
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Positive	54
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Negative	855
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Positive	55
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Negative	423
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Positive	33
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Negative	1,393
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Positive	95
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Negative	713
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Positive	62
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Negative	3,372
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Positive	231
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Negative	2,408
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Positive	175

HTC_TST_DSD	HTS_TST_N_DSD_MN_Age_Sex_Result <5, Unknown Sex, Negative	275
HTC_TST_DSD	HTS_TST_N_DSD_MN_Age_Sex_Result <5, Unknown Sex, Positive	42
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Negative	7,684
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Positive	592
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Negative	7,367
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Positive	560
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Negative	6,155
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Positive	483
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Negative	6,133
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Positive	459
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Negative	10,010
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Positive	785
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Negative	8,042
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Positive	612
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Negative	24,227
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Positive	1,909
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Negative	17,494



HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Positive	1,379
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Negative	2,987
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Positive	267
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Negative	2,094
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Positive	152
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Negative	1,125
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Positive	116
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Negative	298
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Positive	32
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Female, Negative	54
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Female, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Female, Negative	165
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Female, Positive	17
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Male, Negative	130
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Male, Positive	9
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Female, Negative	204
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Female, Positive	24





HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Male, Negative	191
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Male, Positive	13
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Female, Negative	173
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Female, Positive	23
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Male, Negative	160
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Male, Positive	11
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Female, Negative	275
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Female, Positive	46
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Male, Negative	207
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Male, Positive	29
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Female, Negative	673
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Female, Positive	121
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Male, Negative	489
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Male, Positive	87
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Female, Negative	584
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Female, Positive	100
HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Male, Negative	513



HTC_TST_DSD	HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Male, Positive	94
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Negative	37
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Negative	23
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Negative	33
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Negative	25
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Negative	59
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Negative	43
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Negative	148
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Positive	23
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Negative	87
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Positive	7
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Negative	1,780



HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Positive	103
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Negative	1,319
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Positive	91
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Negative	1,670
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Positive	98
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Negative	1,125
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Positive	65
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Negative	2,713
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Positive	158
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Negative	1,658
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Positive	100
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Negative	6,565
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Positive	384
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Negative	4,739
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Positive	274
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 25-29, Male, Negative	1,912
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 25-29, Male, Positive	3



HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 30-34, Male, Negative	1,336
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 30-34, Male, Positive	5
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 35-39, Male, Negative	760
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 35-39, Male, Positive	6
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 40-49, Male, Negative	387
HTC_TST_DSD	HTS_TST_N_DSD_VMMC_Age_Sex_Result 40-49, Male, Positive	1
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	34,360
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	0



	Female, Positive	
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 50+, Female, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: Unknown Age, Female, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: Unknown Age, Female, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: Unknown Age, Male, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: Unknown Age, Male, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: <1, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: <1, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 1-9, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 1-9, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 15-19,	467



	Female, Negative	
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	35
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	673
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	52
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	1,116
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	92
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	2,548
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	201
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	2,079
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	163
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: Unknown Age, Female, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: Unknown Age, Female, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: Unknown Age, Male, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: Unknown Age, Male, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: <1, Negative	57
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: <1, Positive	0



	Positive	
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 1-9, Negative	36
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 1-9, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Pediatric : <5 Negative	35
HTC_TST_TA	Service Delivery Point (Facility) Pediatric : <5 Positive	1
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Female, Negative	1
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Male, Negative	1
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Female, Negative	21
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Female, Positive	1
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Male, Negative	15
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 10-14, Negative	744
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 15-19, Negative	575
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 20-24, Negative	216
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 50+, Negative	42
HTC_TST_TA	Service Delivery Point (Facility) Index: 10-14, Female, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) Index: 10-14, Female, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Index: 10-14, Male, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) Index: 10-14, Male, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Female, Negative	91



HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Female, Positive	13
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Male, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) Index: 15-19, Male, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Female, Negative	128
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Female, Positive	25
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Male, Negative	218
HTC_TST_TA	Service Delivery Point (Facility) Index: 20-24, Male, Positive	38
HTC_TST_TA	Service Delivery Point (Facility) Index: 50+, Female, Negative	471
HTC_TST_TA	Service Delivery Point (Facility) Index: 50+, Female, Positive	93
HTC_TST_TA	Service Delivery Point (Facility) Index: 50+, Male, Negative	380
HTC_TST_TA	Service Delivery Point (Facility) Index: 50+, Male, Positive	76
HTC_TST_TA	Service Delivery Point (Facility) Index: Unknown Age, Female, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) Index: Unknown Age, Female, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Index: Unknown Age, Male, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) Index: Unknown Age, Male, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Index: <1, Negative	274
HTC_TST_TA	Service Delivery Point (Facility) Index: <1, Positive	11
HTC_TST_TA	Service Delivery Point (Facility) Index: 1-9, Negative	164
HTC_TST_TA	Service Delivery Point (Facility) Index: 1-9, Positive	4





HTC_TST_TA	Service Delivery Point (Facility) ANC: 15-19, Negative	302
HTC_TST_TA	Service Delivery Point (Facility) ANC: 15-19, Positive	3
HTC_TST_TA	Service Delivery Point (Facility) ANC: 20-24, Negative	787
HTC_TST_TA	Service Delivery Point (Facility) ANC: 20-24, Positive	41
HTC_TST_TA	Service Delivery Point (Facility) VCT: 10-14, Female, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) VCT: 10-14, Female, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) VCT: 10-14, Male, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) VCT: 10-14, Male, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	131
HTC_TST_TA	Service Delivery Point (Facility) VCT: 15-19, Female, Positive	6
HTC_TST_TA	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) VCT: 15-19, Male, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	154
HTC_TST_TA	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	6
HTC_TST_TA	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	307
HTC_TST_TA	Service Delivery Point (Facility) VCT: 20-24, Male, Positive	13
HTC_TST_TA	Service Delivery Point (Facility) VCT: 50+, Female, Negative	691
HTC_TST_TA	Service Delivery Point (Facility) VCT: 50+, Female, Positive	40
HTC_TST_TA	Service Delivery Point (Facility) VCT: 50+, Male, Negative	564



HTC_TST_TA	Service Delivery Point (Facility) VCT: 50+, Male, Positive	33
HTC_TST_TA	Service Delivery Point (Facility) VCT: Unknown Age, Female, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) VCT: Unknown Age, Female, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) VCT: Unknown Age, Male, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) VCT: Unknown Age, Male, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) VCT: <1, Negative	30
HTC_TST_TA	Service Delivery Point (Facility) VCT: <1, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) VCT: 1-9, Negative	17
HTC_TST_TA	Service Delivery Point (Facility) VCT: 1-9, Positive	0
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 10-14, Female, Negative	0
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 10-14, Female, Positive	0
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 10-14, Male, Negative	0
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 10-14, Male, Positive	0
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 15-19, Female, Negative	8
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 15-19, Female, Positive	0
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 15-19, Male, Negative	0
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 15-19, Male, Positive	0
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 1-9, Unknown Sex, Negative	12
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 1-9, Unknown Sex, Positive	0



HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result <1, Unknown Sex, Negative	26
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result <1, Unknown Sex, Positive	0
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 20-24, Female, Negative	7
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 20-24, Female, Positive	0
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 20-24, Male, Negative	24
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 20-24, Male, Positive	0
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 25-29, Female, Negative	12
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 25-29, Female, Positive	0
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 25-29, Male, Negative	26
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 25-29, Male, Positive	0
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 30-34, Female, Negative	14
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 30-34, Female, Positive	0
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 30-34, Male, Negative	8
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 30-34, Male, Positive	0
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 35-39, Female, Negative	24
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 35-39, Female, Positive	1
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 35-39, Male, Negative	13



HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 35-39, Male, Positive	1
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 40-49, Female, Negative	54
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 40-49, Female, Positive	2
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 40-49, Male, Negative	33
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 40-49, Male, Positive	0
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 50+, Female, Negative	46
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 50+, Female, Positive	1
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 50+, Male, Negative	35
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result 50+, Male, Positive	1
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result Unknown Age, Female, Negative	0
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result Unknown Age, Female, Positive	0
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result Unknown Age, Male, Negative	0
HTC_TST_TA	HTS_TST_N_TA_EW_Age_Sex_Result Unknown Age, Male, Positive	0
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 25-29, Female, Negative	157
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 25-29, Female, Positive	31
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 25-29, Male, Negative	284
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 25-29, Male, Positive	51



HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 30-34, Female, Negative	136
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 30-34, Female, Positive	26
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 30-34, Male, Negative	132
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 30-34, Male, Positive	20
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 35-39, Female, Negative	225
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 35-39, Female, Positive	44
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 35-39, Male, Negative	170
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 35-39, Male, Positive	33
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 40-49, Female, Negative	541
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 40-49, Female, Positive	106
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 40-49, Male, Negative	373
HTC_TST_TA	HTS_TST_N_TA_Index_Age_Sex_Result 40-49, Male, Positive	75
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 25-29, Female, Negative	0
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 25-29, Female, Positive	0
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 25-29, Male, Negative	0
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 25-29, Male, Positive	0
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 30-34, Female, Negative	0



HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 30-34, Female, Positive	0
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 30-34, Male, Negative	0
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 30-34, Male, Positive	0
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 35-39, Female, Negative	0
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 35-39, Female, Positive	0
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 35-39, Male, Negative	0
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 35-39, Male, Positive	0
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 40-49, Female, Negative	0
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 40-49, Female, Positive	0
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 40-49, Male, Negative	0
HTC_TST_TA	HTS_TST_N_TA_Inpat_Age_Sex_Result 40-49, Male, Positive	0
HTC_TST_TA	HTS_TST_N_TA_MN_Age_Sex_Result <5, Unknown Sex, Negative	42
HTC_TST_TA	HTS_TST_N_TA_MN_Age_Sex_Result <5, Unknown Sex, Positive	3
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 25-29, Female, Negative	854
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 25-29, Female, Positive	67
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 25-29, Male, Negative	1,457
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 25-29, Male, Positive	115



HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 30-34, Female, Negative	742
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 30-34, Female, Positive	59
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 30-34, Male, Negative	692
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 30-34, Male, Positive	53
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 35-39, Female, Negative	1,207
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 35-39, Female, Positive	93
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 35-39, Male, Negative	900
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 35-39, Male, Positive	71
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 40-49, Female, Negative	2,915
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 40-49, Female, Positive	227
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 40-49, Male, Negative	2,020
HTC_TST_TA	HTS_TST_N_TA_OtPITC_Age_Sex_Result 40-49, Male, Positive	159
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 25-29, Female, Negative	679
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 25-29, Female, Positive	46
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 30-34, Female, Negative	469
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 30-34, Female, Positive	26
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 35-39, Female, Negative	247



HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 35-39, Female, Positive	19
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 40-49, Female, Negative	62
HTC_TST_TA	HTS_TST_N_TA_PMTCT_Age_Sex_Result 40-49, Female, Positive	4
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result <1, Unknown Sex, Negative	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result <1, Unknown Sex, Positive	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 10-14, Female, Negative	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 10-14, Female, Positive	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 10-14, Male, Negative	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 10-14, Male, Positive	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 15-19, Female, Negative	9
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 15-19, Female, Positive	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 15-19, Male, Negative	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 15-19, Male, Positive	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 1-9, Unknown Sex, Negative	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 1-9, Unknown Sex, Positive	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 20-24, Female, Negative	17
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 20-24, Female, Positive	0





HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 20-24, Male, Negative	28
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 20-24, Male, Positive	1
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 25-29, Female, Negative	25
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 25-29, Female, Positive	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 25-29, Male, Negative	38
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 25-29, Male, Positive	5
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 30-34, Female, Negative	23
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 30-34, Female, Positive	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 30-34, Male, Negative	17
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 30-34, Male, Positive	1
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 35-39, Female, Negative	31
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 35-39, Female, Positive	2
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 35-39, Male, Negative	26
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 35-39, Male, Positive	1
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 40-49, Female, Negative	79
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 40-49, Female, Positive	12
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 40-49, Male, Negative	54



HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 40-49, Male, Positive	5
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 50+, Female, Negative	72
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 50+, Female, Positive	8
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 50+, Male, Negative	55
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result 50+, Male, Positive	6
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result Unknown Age, Female, Negative	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result Unknown Age, Female, Positive	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result Unknown Age, Male, Negative	0
HTC_TST_TA	HTS_TST_N_TA_STI_Age_Sex_Result Unknown Age, Male, Positive	0
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 25-29, Female, Negative	2
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 25-29, Male, Negative	2
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 30-34, Female, Negative	2
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 30-34, Male, Negative	3
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 35-39, Female, Negative	10
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 35-39, Male, Negative	4
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 40-49, Female, Negative	30
HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 40-49, Female, Positive	1



HTC_TST_TA	HTS_TST_N_TA_TBC_Age_Sex_Result 40-49, Male, Negative	13
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 25-29, Female, Negative	208
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 25-29, Female, Positive	8
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 25-29, Male, Negative	389
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 25-29, Male, Positive	20
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 30-34, Female, Negative	202
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 30-34, Female, Positive	10
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 30-34, Male, Negative	144
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 30-34, Male, Positive	5
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 35-39, Female, Negative	327
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 35-39, Female, Positive	21
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 35-39, Male, Negative	204
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 35-39, Male, Positive	11
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 40-49, Female, Negative	793
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 40-49, Female, Positive	46
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 40-49, Male, Negative	548
HTC_TST_TA	HTS_TST_N_TA_VCT_Age_Sex_Result 40-49, Male, Positive	33

HTC_TST_TA	HTS_TST_N_TA_VMMC_Age_Sex_Result 25-29, Male, Negative	216
HTC_TST_TA	HTS_TST_N_TA_VMMC_Age_Sex_Result 30-34, Male, Negative	150
HTC_TST_TA	HTS_TST_N_TA_VMMC_Age_Sex_Result 30-34, Male, Positive	1
HTC_TST_TA	HTS_TST_N_TA_VMMC_Age_Sex_Result 35-39, Male, Negative	84
HTC_TST_TA	HTS_TST_N_TA_VMMC_Age_Sex_Result 35-39, Male, Positive	1
HTC_TST_TA	HTS_TST_N_TA_VMMC_Age_Sex_Result 40-49, Male, Negative	42
HTS_SELF_TA	HTS_SELF_N_TA	0
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 10-14, Male, Unassisted	0
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 15-19, Female, Unassisted	0
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 15-19, Male, Unassisted	0
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 20-24, Female, Unassisted	0
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 20-24, Male, Unassisted	0
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 25-29, Female, Unassisted	0
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 25-29, Male, Unassisted	0
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 30-34, Female, Unassisted	0
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 30-34, Male, Unassisted	0
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 35-39, Female, Unassisted	0
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 35-39, Male,	0



	Unassisted	
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 40-49, Female, Unassisted	0
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 40-49, Male, Unassisted	0
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 50+, Female, Unassisted	0
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest 50+, Male, Unassisted	0
HTS_SELF_TA	HTS_SELF_N_TA_Age_Sex_HIVSelfTest Unknown Age, Male, Unassisted	0
HTS_SELF_TA	HTS_SELF_N_TA_HIVSelfTest Unassisted	0
HTS_SELF_TA	HTS_SELF_N_TA_HIVSelfTestUser Unassisted - Self	0
HTS_SELF_TA	HTS_SELF_N_TA_HIVSelfTestUser Unassisted - Sex Partner	0
HTS_SELF_DSD	HTS_SELF_N_DSD	13,891
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 10-14, Male, Directly-Assisted	0
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Directly-Assisted	0
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Unassisted	69
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Directly-Assisted	0
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Unassisted	69
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Directly-Assisted	0
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Unassisted	347
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Directly-Assisted	0
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Unassisted	347



HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Directly-Assisted	0
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Unassisted	556
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Directly-Assisted	0
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Unassisted	556
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Directly-Assisted	0
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Unassisted	556
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Directly-Assisted	0
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Unassisted	556
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Directly-Assisted	0
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Unassisted	902
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Directly-Assisted	0
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Unassisted	902
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Directly-Assisted	0
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Unassisted	2,432
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Directly-Assisted	0
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Unassisted	2,432
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Directly-Assisted	0



HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Unassisted	2,084
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Directly-Assisted	0
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Unassisted	2,084
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest Unknown Age, Male, Directly-Assisted	0
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Directly-Assisted	0
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Unassisted	13,891
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Self	2,778
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Sex Partner	11,113

### Implementing Mechanism Details

<b>Mechanism ID: 18220</b>	<b>Mechanism Name: Global Health Supply Chain Program</b>
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Global Health Supply Chain Program	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 979,808</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 979,808</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	979,808

### Cross-Cutting Budget Attribution(s)

(No data provided.)



**Budget Code Information**

<b>Mechanism ID:</b> 18220		
<b>Mechanism Name:</b> Global Health Supply Chain Program		
<b>Prime Partner Name:</b> Global Health Supply Chain Program		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HBHC	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HKID	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HVTB	179,690
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	PDCS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HLAB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HVSI	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	OHSS	260,000
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	CIRC	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HMBL	0





Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	100,118
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	440,000
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 18252</b>	<b>Mechanism Name: Quality HIV/AIDS Services through Government of Botswana</b>
----------------------------	---



Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Government of Botswana	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: Yes	Managing Agency: HHS/CDC

<b>Total All Funding Sources: 2,162,504</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 670,341</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 2,832,845</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	2,162,504

**Cross-Cutting Budget Attribution(s)**

Motor Vehicles: Purchased	60,000
Adolescent Girls and Young Women (AGYW)	200,000

**Budget Code Information**

<b>Mechanism ID: 18252</b>		
<b>Mechanism Name: Quality HIV/AIDS Services through Government of Botswana</b>		
<b>Prime Partner Name: Government of Botswana</b>		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HBHC	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HKID	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>



Care	HVTB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	PDCS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HLAB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HVSI	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	OHSS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	CIRC	447,100
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HMBL	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HMIN	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVAB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVCT	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVOP	200,000
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	IDUP	0



Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	110,000
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	1,355,404
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	50,000

### Implementing Mechanism Indicator Information

Indicator Number	Label	2019
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	10
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	12
PMTCT_ART_DSD	New on ART	10
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	12
PMTCT_STAT_DSD	Number of new ANC and L&D clients	12
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 25-29, Female	3
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 30-34, Female	6
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 35-39, Female	2
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 40-49, Female	1
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Known at Entry Positive	3

PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Known at Entry Positive	6
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Known at Entry Positive	2
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Known at Entry Positive	1
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 25-29, Female	3
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 30-34, Female	6
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 35-39, Female	2
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 40-49, Female	1
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	2,631
VMMC_CIRC_DSD	By Age: 10-14	920
VMMC_CIRC_DSD	By Age: 15-19	789
VMMC_CIRC_DSD	By Age: 20-24	264
VMMC_CIRC_DSD	By Age: 25-29	263
VMMC_CIRC_DSD	By Age: 50+	53
VMMC_CIRC_DSD	Sum of age disaggregates (Prior to FY15)	2,026
VMMC_CIRC_DSD	Sum of age disaggregates (FY15-Current)	2,289
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	2,630
VMMC_CIRC_DSD	VMMC_CIRC_N_DSD_Age_Sex 30-34, Male	184
VMMC_CIRC_DSD	VMMC_CIRC_N_DSD_Age_Sex 35-39, Male	105
VMMC_CIRC_DSD	VMMC_CIRC_N_DSD_Age_Sex 40-49, Male	53
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	7
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	7
PMTCT_EID_DSD	Sum of Infant Age disaggregates	7
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	343
TX_CURR_DSD	Age/Sex: 15-19 Male	1
TX_CURR_DSD	Age/Sex: 15-19 Female	4



TX_CURR_DSD	Sum of age/sex disaggregates	5
TX_CURR_DSD	Age/Sex: 10-14 Male	13
TX_CURR_DSD	Age/Sex: 10-14 Female	10
TX_CURR_DSD	Age/Sex: 20-24 Male	1
TX_CURR_DSD	Age/Sex: 50+ Male	28
TX_CURR_DSD	Age/Sex: 20-24 Female	3
TX_CURR_DSD	Age/Sex: 50+ Female	41
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	22
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	9
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive	30
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	15
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive	36
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive	19
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive	54
TX_CURR_DSD	TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive	57
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	15
TX_NEW_DSD	By Age/Sex: 1-9	1
TX_NEW_DSD	By Age/Sex: 50+ Male	1
TX_NEW_DSD	By Age/Sex: 50+ Female	1
TX_NEW_DSD	Sum of Age/Sex disaggregates	2
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive	3
TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive	3



TX_NEW_DSD	TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive	6
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	43
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	45
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	28
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	3
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	10
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	29
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	3



TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	11
------------	---	----

**Implementing Mechanism Details**

<b>Mechanism ID: 18253</b>	<b>Mechanism Name: Community HIV Testing and Counseling and KP Support</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: University of Maryland	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 3,507,926</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 3,507,926</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	3,507,926

**Cross-Cutting Budget Attribution(s)**

Motor Vehicles: Purchased	190,000
---------------------------	---------

**Budget Code Information**

<b>Mechanism ID:</b>	18253	
<b>Mechanism Name:</b>	Community HIV Testing and Counseling and KP Support	
<b>Prime Partner Name:</b>	University of Maryland	
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>





Care	HBHC	1,481,348
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HKID	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HVTB	260,000
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	PDCS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HLAB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HVSI	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	OHSS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	CIRC	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HMBL	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HMIN	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVAB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVCT	917,966



Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	848,612
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2019
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	24,011
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Negative	41
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Negative	490
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Positive	26
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Negative	260



HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Positive	13
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Female, Negative	690
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Female, Positive	36
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Negative	1,160
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Positive	61
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: <1, Negative	34
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 1-9, Negative	13
HTC_TST_DSD	Service Delivery Point (Community) Other: 15-19, Female, Negative	42
HTC_TST_DSD	Service Delivery Point (Community) Other: 15-19, Female, Positive	3
HTC_TST_DSD	Service Delivery Point (Community) Other: 20-24, Female, Negative	904
HTC_TST_DSD	Service Delivery Point (Community) Other: 20-24, Female, Positive	49
HTC_TST_DSD	Service Delivery Point (Community) Other: 20-24, Male, Negative	435
HTC_TST_DSD	Service Delivery Point (Community) Other: 20-24, Male, Positive	26
HTC_TST_DSD	Service Delivery Point (Community) Other: 50+, Female, Negative	1,513
HTC_TST_DSD	Service Delivery Point (Community) Other: 50+, Female, Positive	89
HTC_TST_DSD	Service Delivery Point (Community) Other: 50+, Male, Negative	2,550
HTC_TST_DSD	Service Delivery Point (Community) Other: 50+, Male, Positive	140



HTC_TST_DSD	Service Delivery Point (Community) Other: <1, Negative	136
HTC_TST_DSD	Service Delivery Point (Community) Other: <1, Positive	7
HTC_TST_DSD	Service Delivery Point (Community) Other: 1-9, Negative	34
HTC_TST_DSD	Service Delivery Point (Community) Other: 1-9, Positive	2
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Negative	18
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Positive	6
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Negative	127
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Positive	33
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Negative	101
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Positive	32
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Female, Negative	248
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Female, Positive	77
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Negative	269
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Positive	67
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: <1, Negative	137
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: <1, Positive	7
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 1-9, Negative	34
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 1-9, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29,	129

	Female, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Female, Positive	6
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Male, Negative	208
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Male, Positive	11
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Female, Negative	8
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Male, Negative	477
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Male, Positive	26
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Female, Negative	422
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Female, Positive	23
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Male, Negative	697
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Male, Positive	37
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Female, Negative	992
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Female, Positive	53
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Male, Negative	981
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Male, Positive	51
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Negative	74
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Female, Positive	26
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Negative	138



	Male, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 25-29, Male, Positive	49
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Negative	41
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Female, Positive	17
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Negative	191
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 30-34, Male, Positive	61
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Female, Negative	135
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Female, Positive	40
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Negative	218
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 35-39, Male, Positive	64
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Female, Negative	318
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Female, Positive	94
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Negative	283
HTC_TST_DSD	HTS_TST_N_DSD_NdxMod_Age_Sex_Result 40-49, Male, Positive	80
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 25-29, Female, Negative	137
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 25-29, Female, Positive	9
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 25-29, Male, Negative	224
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 25-29, Male, Positive	17



	Male, Positive	
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 30-34, Female, Negative	16
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 30-34, Female, Positive	4
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 30-34, Male, Negative	784
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 30-34, Male, Positive	48
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Female, Negative	927
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Female, Positive	53
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Male, Negative	1,279
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Male, Positive	73
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Female, Negative	2,177
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Female, Positive	125
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Male, Negative	2,154
HTC_TST_DSD	HTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Male, Positive	122
HTS_SELF_DSD	HTS_SELF_N_DSD	3,858
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Unassisted	19
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Unassisted	19
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Unassisted	96
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Unassisted	96



HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Unassisted	154
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Unassisted	154
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Unassisted	154
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Unassisted	154
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Unassisted	252
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Unassisted	252
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Unassisted	675
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Unassisted	675
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Unassisted	579
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Unassisted	579
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Unassisted	3,858
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Self	772
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Sex Partner	3,086

### Implementing Mechanism Details

<b>Mechanism ID: 18458</b>	<b>Mechanism Name: BCPP</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Government of Botswana	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:





<b>Total All Funding Sources: 0</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID: 18458</b>		
<b>Mechanism Name: BCPP</b>		
<b>Prime Partner Name: Government of Botswana</b>		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HBHC	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HKID	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HVTB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	PDCS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HLAB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HVSI	0



Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount

Approved



Treatment	PDTX	0
-----------	------	---

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 18685</b>	<b>Mechanism Name: HRH2030</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Chemonics International	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 850,000</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 850,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	850,000

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b>	18685	
<b>Mechanism Name:</b>	HRH2030	
<b>Prime Partner Name:</b>	Chemonics International	
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>



Care	HBHC	800,000
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HKID	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HVTB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	PDCS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HLAB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HVSI	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	OHSS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	CIRC	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HMBL	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HMIN	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVAB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVCT	0



Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	50,000
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

Mechanism ID: 70000	TBD: Yes
REDACTED	

### Implementing Mechanism Details

Mechanism ID: 70001	TBD: Yes
REDACTED	

### Implementing Mechanism Details



<b>Mechanism ID: 70003</b>	<b>Mechanism Name: [Placeholder - 70003 Botswana HHS/CDC]</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: WHO/AFRO	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
<b>Total All Funding Sources: 0</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID: 70003</b>		
<b>Mechanism Name: [Placeholder - 70003 Botswana HHS/CDC]</b>		
<b>Prime Partner Name: WHO/AFRO</b>		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HBHC	40,500
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HKID	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HVTB	27,000



Strategic Area	Budget Code	Planned Amount
Care	PDCS	13,500
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount



Prevention	MTCT	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	HTXD	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	HTXS	40,500
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	PDTX	13,500

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 70004</b>	<b>Mechanism Name: [Placeholder - 70004 Botswana HHS/CDC]</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Association of Public Health Laboratories	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
<b>Total All Funding Sources: 0</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>

### Cross-Cutting Budget Attribution(s)

(No data provided.)





**Budget Code Information**

<b>Mechanism ID:</b> 70004		
<b>Mechanism Name:</b> [Placeholder - 70004 Botswana HHS/CDC]		
<b>Prime Partner Name:</b> Association of Public Health Laboratories		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HBHC	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HKID	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	HVTB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Care	PDCS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HLAB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	HVSI	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Governance and Systems	OHSS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	CIRC	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HMBL	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>



Prevention	HMIN	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVAB	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVCT	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	HVOP	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	IDUP	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Prevention	MTCT	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	HTXD	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	HTXS	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>
Treatment	PDTX	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 70013</b>	<b>TBD: Yes</b>
<b>REDACTED</b>	



### Implementing Mechanism Details

Mechanism ID: 70014	TBD: Yes
REDACTED	

### Implementing Mechanism Details

Mechanism ID: 70015	TBD: Yes
REDACTED	

### Implementing Mechanism Details

Mechanism ID: 70016	TBD: Yes
REDACTED	

### Implementing Mechanism Details

Mechanism ID: 70017	TBD: Yes
REDACTED	



**Agency Information - Costs of Doing Business**  
**U.S. Agency for International Development**

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline Amount
Computers/IT Services		141,042		141,042	0	141,042
ICASS		618,000		618,000	0	618,000
Institutional Contractors		291,725	0	291,725	0	291,725
Management Meetings/Professional Development		219,000		219,000	0	219,000
Non-ICASS Administrative Costs		363,984		363,984	0	363,984
Peace Corps Volunteer Costs				0	0	0
Staff Program Travel		154,000	0	154,000	0	154,000
USG Staff Salaries and Benefits - Internationally Recruited		1,167,589	0	1,167,589	0	1,167,589
USG Staff Salaries and Benefits -		1,168,906	0	1,168,906	0	1,168,906

Approved



Locally Recruited						
<b>Total</b>	<b>0</b>	<b>4,124,246</b>	<b>0</b>	<b>4,124,246</b>	<b>0</b>	<b>4,124,246</b>

**U.S. Department of Defense**

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline Amount
Institutional Contractors				0	0	0
Peace Corps Volunteer Costs				0	0	0
Staff Program Travel		21,000		21,000	0	21,000
USG Staff Salaries and Benefits - Internationally Recruited		0		0	0	0
USG Staff Salaries and Benefits - Locally Recruited		161,000		161,000	0	161,000
<b>Total</b>	<b>0</b>	<b>182,000</b>	<b>0</b>	<b>182,000</b>	<b>0</b>	<b>182,000</b>

**U.S. Department of Health and Human Services/Centers for Disease Control and Prevention**



Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline Amount
Capital Security Cost Sharing		173,758		173,758	0	173,758
Computers/IT Services		101,162		101,162	0	101,162
ICASS		1,421,749		1,421,749	0	1,421,749
Management Meetings/Professional Development		25,000		25,000	0	25,000
Non-ICASS Administrative Costs		919,144		919,144	0	919,144
Staff Program Travel	0	450,000		450,000	0	450,000
USG Staff Salaries and Benefits - Internationally Recruited	2,196,250	0		2,196,250	0	2,196,250
USG Staff Salaries and Benefits - Locally Recruited	0	2,268,828		2,268,828	0	2,268,828
<b>Total</b>	<b>2,196,250</b>	<b>5,359,641</b>	<b>0</b>	<b>7,555,891</b>	<b>0</b>	<b>7,555,891</b>

## U.S. Department of State



Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline Amount
Institutional Contractors				0	0	0
Peace Corps Volunteer Costs				0	0	0
Staff Program Travel		0		0	11,000	11,000
USG Staff Salaries and Benefits - Internationally Recruited		0		0	101,861	101,861
USG Staff Salaries and Benefits - Locally Recruited		57,662		57,662	70,740	128,402
<b>Total</b>	<b>0</b>	<b>57,662</b>	<b>0</b>	<b>57,662</b>	<b>183,601</b>	<b>241,263</b>

**U.S. Peace Corps**

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline Amount
Non-ICASS Administrative		148,123		148,123	0	148,123

Approved



Costs						
Non-ICASS Motor Vehicles		45,000		45,000	0	45,000
Peace Corps Volunteer Costs		2,510,179		2,510,179	0	2,510,179
Staff Program Travel		89,045		89,045	0	89,045
USG Staff Salaries and Benefits - Internationally Recruited		0		0	0	0
USG Staff Salaries and Benefits - Locally Recruited		376,569		376,569	0	376,569
<b>Total</b>	<b>0</b>	<b>3,168,916</b>	<b>0</b>	<b>3,168,916</b>	<b>0</b>	<b>3,168,916</b>